前往化源商城

14480-75-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CYP273
Protocol: Tox21 Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a BioRaptr Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). Compounds dissolved in DMSO and positive control (furafyllline) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000075213 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000689059 uM-Replicate_1Activity at 0.0001619730 uM-Replicate_1Activity at 0.0003751800 uM-Replicate_1Activity at 0.0007781017 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00657 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-3.5643-2.3504-2.9312-2.3657-2.8224-2.60180.03942.8539-0.9099-0.8614-3.0049-2.5808-0.7-3.5643QC'd by SIGMAInactive0
Inactive0004-4.9449-1.1401-4.88281.72781.7167-2.1117-5.69640.39330.89390.1314-2.73353.195-4.9521-4.9449QC'd by SIGMAInactive0
Inactive00042.7107-2.18841.39851.45820.7693-2.47871.522.89860.9702-0.02532.12932.77661.5392.7107QC'd by EnamineInactive0
Inactive0004-2.1522-2.3143-3.894-2.36983.0635-2.9724-0.6981.807-0.3874-2.23870.0851-4.19653.0171-2.1522QC'd by SIGMAInactive0
Inactive0-4.34892.25260.8543-15.2749-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3957-1.8486-1.8251-1.3415-0.2999-5.8043-1.46250.1520.0394-2.6869-2.4228-2.2664-9.6519-14.3957QC'd by SIGMAInactive0-4.09892.18760.881
Inactive0-4.39891.34430.8661-18.2112-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.0093-2.34660.81450.3878-0.5249-2.2045-0.0596-0.3675-2.1137-2.5302-0.6582-8.8446-8.7305-16.0093QC'd by AcrosInactive0-4.19891.62660.9372
Inactive0-4.37131.3310.7782-33.4439-3.50340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.5366-4.0189-0.7745-2.4487-0.7353-13.4714-1.9963-2.0808-1.5803-2.9931-5.0804-13.0346-7.2628-16.8143-29.5366QC'd by LightBiologicalsInactive0-4.37131.22210.9463
Inactive0-4.14891.62660.9461-28.1716-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.143-1.7608-0.23880.22480.5264-2.4986-0.1313-2.2365-0.2423-3.4362-3.0971-3.2181-11.2156-20.143QC'd by EnamineInhibitor79.640731.491610Partial curve; partial efficacy; poor fit-4.09892.58840.988
Inhibitor79.640737.878410Partial curve; partial efficacy; poor fit-4.09892.33320.6037-41.3784-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14860.0477-0.2424-0.1109-17.1482-2.60430.09871.3021-8.8121-0.6811-2.6079-6.0005-11.8578-31.1486QC'd by LightBiologicalsInhibitor70.979933.811310Partial curve; partial efficacy; poor fit-4.14891.47870.9532
Inactive0-4.14891.3310.6595-35.6335-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.36121.8269-1.26512.0528-1.3342-1.1508-1.3078-0.329-8.12350.9213-0.3901-8.3475-13.4823-26.3612QC'd by LightBiologicalsInhibitor63.260940.716221Partial curve; partial efficacy-4.19891.55790.9889
Inhibitor31.7055100.219240Partial curve; high efficacy-4.49891.41630.9793-102.2947-2.0755-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.79751.59931.9578-0.4182-5.9156-12.3257-6.81250.6301-0.9357-7.8675-21.9718-39.1747-68.2733-88.7975QC'd by SIGMAInhibitor28.2576108.402740Partial curve; high efficacy-4.54891.24750.9984
Inactive0-4.44891.53860.9285-23.7863140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.48852.58192.144-0.92281.57780.3813-0.7273-0.01780.48032.4385-0.728-9.9293-11.8247-21.4885QC'd by SIGMAInactive0-4.39891.62590.9598
Inhibitor9.333739.896721Complete curve; partial efficacy-5.02992.04370.9899-39.89670-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.3129-0.2423-0.4463-0.29990.64780.36361.006-0.49871.2825-1.1546-7.8589-17.895-35.8398-36.3129QC'd by LightBiologicalsInhibitor11.750456.388421Partial curve; partial efficacy-4.92991.1110.9845
Inhibitor31.7055101.457340Partial curve; high efficacy-4.49891.1110.9982-102.7597-1.3024-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-82.349-1.7206-3.1014-1.0307-0.462-0.0614-0.5481-3.1286-4.6801-13.1432-23.5612-42.1146-67.192-82.349QC'd by SIGMAInhibitor25.184689.509140Partial curve; high efficacy-4.59891.37230.9943
Inactive0-4.39891.37230.9408-30.7143-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.2619-3.9038-4.25970.95220.2767-0.086-3.7725-0.0863-0.3476-4.4856-5.6587-11.4378-17.5999-27.2619QC'd by EnamineInactive0-4.39891.37230.9104
Inhibitor0.0291.537495Complete curve; high efficacy-7.69891.210.9985-95.5053-3.9679-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.9758-10.1145-26.2532-42.3865-67.4835-79.9456-90.8539-91.593-94.2489-95.4721-96.0956-96.1267-97.0582-96.9758QC'd by SIGMAInhibitor0.141694.840291Complete curve; high efficacy-6.84891.210.9987
Inhibitor70.979957.401421Partial curve; partial efficacy-4.14891.46410.9678-60.4859-3.0846-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.8227-1.5241-1.1304-2.119-3.4583-2.7138-4.9163-1.3699-5.0741-7.7268-8.2608-10.3758-24.1789-45.8227QC'd by TCIInhibitor63.260959.370621Partial curve; partial efficacy-4.19891.82650.9826
Inhibitor31.705588.458340Partial curve; high efficacy-4.49891.24750.9907-90.0614-1.6031-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.0646-2.1792-0.7242-0.9217-2.0267-1.1711-1.4022-1.5555-4.0648-12.1704-19.1709-32.2561-64.0802-73.0646QC'd by SIGMAInhibitor31.705586.838540Partial curve; high efficacy-4.49891.1110.9934
Inhibitor7.09899.944883Complete curve; high efficacy-5.14891.34430.9949-102.6257-2.681-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-98.8687-2.2636-1.9377-0.2674-0.3864-3.2139-8.5636-4.0834-14.5383-36.543-60.2337-91.3595-96.848-98.8687QC'd by TCIInhibitor5.638199.072784Complete curve; high efficacy-5.24891.62660.998
Inhibitor14.162399.52242Partial curve; high efficacy-4.84890.70.9894-100.6417-1.1197-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.2822-1.4919-2.9847-0.2649-1.6478-3.8502-2.8959-7.6423-18.6375-36.1235-44.1844-53.91-71.7844-88.2822QC'd by SIGMAInhibitor17.829395.774281Complete curve; high efficacy-4.74891.210.9995
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cytochrome P450 1B1
External ID: CHEMBL4768634
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2020
Volume: 193
First Page: 112235
Last Page: 112235
DOI: 10.1016/j.ejmech.2020.112235

Target ChEMBL ID: CHEMBL4878
ChEMBL Target Name: Cytochrome P450 1B1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard UnitsActivity Comment
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:Burkholderia multivorans
External ID: HMS1625
Protocol: The fix-reporter plasmid was conjugated into this strain which the stably integrates into the chromosome using the mini-Tn7 system (PMID: 15908923). This plasmid consists of the fixK promoter, which is a target of the fixLJ pathway driving expression of GFP.
The day before screen an overnight culture of B. multivorans strain VC7102, with fix reporter, is set up in tryptic soy broth (TSB) at 37 degrees C with shaking. The day of the screen the overnight culture is diluted 1:100 in fresh tryptic soy broth.
The day of the screen, 30 microL of tryptic soy broth (TSB) is pipetted into columns 1-22 of a 384-well plate (Corning 3764) using the Combi multidrop dispenser. To column 24, 30 microL of TSB containing 78 microM of Benserazide TSB is added for a positive control. To column 23, 30 microL of TSB containing with DMSO (0.078% v/v in TSB) is added for a negative control. 300 nL of each compound are pin-transferred to each plate. For every compound plate 2 replicate assay plates are set up. 30 microL of the 1:100 diluted-B. multivorans strain VC7102 is added to each well using the Combi. Initial OD600 and GFP are measured using the PerkinElmer EnVision. Plates are stacked 5 high, covered with lids and incubated at 37 degrees C overnight (~18 h).
The following day, assay plates are read using a PerkinElmer EnVision (600 nm filter and GFP).
Positive control: Benserazide 39 microM in column 24 (No positive control was used for plates 2089 & 2090; Plates 2091-2093: columns 1 & 24)
Negative control: DMSO 300 nL/well in column 23 (For plates 2089 & 2090 negative controls were located in columns 2 & 24; plates 2091-2093: columns 2 & 23)
Comment: Analysis method:
For each compound well, the initial GFP value was subtracted from overnight GFP value to calculate the deltaGFP. The mean and standard deviation of the negative control wells deltaGFP (column 23) on both replicate plates was calculated. Wells with replicate average deltaGFP at least 3 standard deviations above the plate negative control deltaGFP average were scored as potential positives.

To determine activity scores, Z-scores were calculated for each replicate separately based on the replicate negative control deltaGFP plate average and standard deviation. The replicate average deltaGFP Z-scores were used for activity scores, with activity score of 100 set to Z-score = 4 and activity score = 0 (no activity) set to Z-score = 0. Z-scores > 4 were considered activity score = 100, and Z-scores < 0 were considered activity score = 0.
Avg_deltaGFP_Z-scoreAbsorbance_T0_AGFP_T0_AAbsorbance_T0_BGFP_T0_BAbsorbance_AGFP_AAbsorbance_BGFP_BdeltaGFP_AdeltaGFP_BAvg_deltaGFPdeltaGFP_A_Z-scoredeltaGFP_B_Z-score
-1.270.05825403560.05725477650.32326537670.3242670642113411122877118144-1.02538-1.51489
0.670.0624266120.0624127100.33225889350.33425870491623231743391683310.3877340.95318
-0.330.05925207730.05925090750.35426732820.3532672667152509163592158050-0.303321-0.354548
10.05924689030.0624661270.34126393810.34326573121704781911851808320.7401411.26456
0.740.10620472210.10720465420.56826607620.57126491096135416025676080540.5436960.932316
-0.660.09221234000.09121483410.52927175620.5272686607594162538266566214-0.115128-1.20669
-2.80.08421991470.08622312650.51327273860.512708166528239476901502570-2.3563-3.24802
-1.960.1121445580.10921539230.526876750.4922666280543117512357527737-1.8505-2.06856
-1.140.10420993670.10121425170.52326817780.5182664243582411521726552068-0.514625-1.7569
-1.270.0621639510.0621890320.47927247140.4792724846560763535814548288-1.25059-1.28825
0.440.11220635890.1121021270.54826852200.53626783436216315762165989240.8187310.0557383
-2.910.0821580040.07921702680.45726695940.4572657682511590487414499502-2.92231-2.8983
-0.490.09520760050.09621319850.52626668050.5242683829590800551844571322-0.229425-0.755007
-0.90.06220905540.06221416370.49726735090.4912677205582955535568559262-0.496131-1.29644
-0.250.11620795900.11521215660.52426775490.52526804075979595588415784000.0139578-0.522249
-2.520.06222558760.06122872190.51327838280.5092781307527952494088511020-2.36606-2.67629
-0.990.06521568750.06421851480.51427183540.5142737090561479551942556710-1.22625-0.751747
0.20.07622487490.07422362870.49828542360.49428440086054876077216066040.425044-0.0214336
-0.390.05921551930.06121585430.5327397010.5262750103584508591560588034-0.243403-0.538384
2.080.0821516730.07921560070.52828023590.52528361806506866801736654301.865212.29612
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Center for Chemical Genomics, University of Michigan 靶标:N/A
External ID: TargetID_659_CEMA
Protocol: Black, standard capacity streptavidin-coated 384-well plates (Pierce 15407) were first washed with 50 L of phosphate buffer (100 mM, pH 7.0; PB7) three times using a Biotek 405 ELX plate washer. Subsequently, 5 L of biotinylated pre-miRNA substrate (500 nM final) was dispensed into the plate using a Multidrop Combi Reagent Dispenser (Thermo Scientific). Plates were then centrifuged for 1 min at 1,000 RPM (223 g), sealed with plate tape, and incubated overnight at 4 C. The following morning, plates were washed three times with 50 L of PB7, followed by the addition of 5 L of Dicer digest buffer (20 mM Tris, 12 mM NaCl, 2.5 mM MgCl2, 1 mM fresh DTT, and 4.5% DMSO) and centrifugation. Compounds (50 nL of 5 mM DMSO stock, 25 M final) were then added into the sample wells using a Sciclone (Caliper) liquid handler with V&P pintool; the same volume of DMSO was added to the control wells. The plates were incubated at 25 C for 15 min before addition of 5 L of digest buffer containing 217 g/nL Dicer (108 g/mL Dicer, 5% glycerol and 0.01% Triton X-100 final, excess with respect to pre-miRNA). For the positive control wells, digest buffer without Dicer was added. The plates were centrifuged again and resealed before being placed in a 37 C incubator for 5 h. After Dicer cleavage, plates were washed three times with 50 L of PB7. mTet-HRP in PB7 (10 L, 750 nM final) was then dispensed into each well. The plates were subsequently centrifuged, sealed, and incubated at 25 C for 2 h. Plates were then washed three times with 50 L of wash buffer (2 mM imidazole, 260 mM NaCl, 0.5 mM EDTA, 0.1% Tween-20, pH 7.0), followed by washing three additional times with 50 L of PB7. Finally, SuperSignal West Pico (25 L; Pierce) was added, the plates were incubated at 25 C for 5 min, and chemiluminescence signal was detected using a PHERAstar plate reader using LUM plus module (BMG Labtech).
Comment: The activity outcome is based on a Z-score (number of standard deviations from the negative control mean) of 3 or higher on at least 50% times that the sample was screened.

For instance, if the sample was screened in n=4 runs, it would be considered active only if it had a Z-score of 3 or above in at least 2 runs.
Z_SCORE
2.91
-0.56
0.61
2.15
0.54
-0.32
1.12
-0.07
0.61
1.55
-0.77
-0.76
-2.08
0.67
-0.35
0.17
-1.42
-0.64
-5.35
1.42
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ATLMIPE3-IL2
Protocol: Plate log growing ED40515 -IL2 cells: 1000cells/ well in 5uL phenol red free RPMI +5% FBS +1x p/s, Glutamine using 1536 well white griener tissue culture plates and multidrop cassette acoustic dispensing Columns 1 and 3 DMSO Columns 2 and 4, 9.2 uM Bortezomib Incubate 48 hours for celltiter glo 37C with 5%CO2 and 95% humidity with low evaporation lids Dispense 3 uL per well of cell titer glo with multidrop Incubate for 15 minutes at RT Read on VL/2 using Luminesence Wheel (Filter A)
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis.CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity.at.0.0003926931.uMActivity.at.0.0007804147.uMActivity.at.0.00118.uMActivity.at.0.00232.uMActivity.at.0.00353.uMActivity.at.0.00468.uMActivity.at.0.00703.uMActivity.at.0.014.uMActivity.at.0.021.uMActivity.at.0.041.uMActivity.at.0.063.uMActivity.at.0.122.uMActivity.at.0.190.uMActivity.at.0.286.uMActivity.at.0.563.uMActivity.at.0.859.uMActivity.at.1.138.uMActivity.at.1.709.uMActivity.at.3.373.uMActivity.at.5.124.uMActivity.at.9.921.uMActivity.at.15.37.uMActivity.at.29.76.uMActivity.at.46.08.uMActivity.at.92.17.uMCompound.QC
Inactive0-4.72923.06540.96239.547110.4177-2.10 0 0 0 0 0 0 0 0 0 05.6022104.2237100.4246111.537113.278104.5883115.9013118.2206116.1988108.286272.51675.6022QC'd by NCGCChem
Inactive0594.579297.6123102.947899.8003105.6959101.965105.2395107.2333115.1756113.402496.876194.5792QC'd by NCGCChem
Inactive05118.6862122.5086119.6416121.4823121.5344119.0353122.0707119.7306119.2832118.9869119.6097118.6862QC'd by Tocris
Activator16.626135.25420Partial curve; high efficacy-4.77922.72020.963177.815113.0692-2.20 0 0 0 0 0 0 0 0 0 078.5161113.5692112.8167111.4636114.2791108.5015116.939114.3917112.9036110.650697.969378.5161QC'd by Tocris
Inactive11.770416.41720Complete curve; high efficacy; poor fit-4.92924.95490.661995.8341112.251340 0 0 0 0 0 0 0 0 0 095.4869103.7513106.3488110.402114.2577113.5346119.5724112.7915113.2464116.108199.181695.4869QC'd by Tocris
Inactive0-4.42924.95490.9697-32.1898108.8199-30 0 0 0 0 0 0 0 0 0 01.164105.3944105.2818103.049797.7276115.3459111.0574111.7252112.9196115.2357112.13391.164QC'd by Tocris
Activator29.565948.60710Partial curve; high efficacy; poor fit-4.52921.10.823964.4214113.0285-30 0 0 0 0 0 0 0 0 0 076.6898115.0285116.0876115.7011112.8082115.8435105.692112.2303104.9467107.3798105.46676.6898QC'd by Tocris
Activator23.48542.03280Partial curve; high efficacy-4.62924.0950.901568.4355110.4683-30 0 0 0 0 0 0 0 0 0 072.122113.3297114.1347103.636115.0097115.7355111.7744109.2314106.9456106.7162103.826472.122QC'd by Tocris
Inactive0-4.87922.24810.96962.8281109.6245-2.10 0 0 0 0 0 0 0 0 0 09.749696.0271105.5671105.6287113.2706112.4076114.1956118.5284112.32598.287645.44369.7496QC'd by Tocris
Inactive0-4.62924.0950.97997.2433109.0947-2.10 0 0 0 0 0 0 0 0 0 014.4101103.9944104.763110.258107.084116.4146111.9569110.6255112.9625102.925593.556714.4101QC'd by Tocris
Inactive0-5.77921.64360.99441.2985114.9257-1.10 0 0 0 0 0 0 0 0 0 00.8492113.1907113.1253114.458115.3332116.5149113.1099102.975250.73724.15761.89510.8492QC'd by Tocris
Inactive37.221230.41770Partial curve; high efficacy; poor fit-4.42924.95490.723777.1455107.563240 0 0 0 0 0 0 0 0 0 083.881897.5632107.1339104.9893111.5954112.5168105.1165104.3329111.0954109.8131110.13683.8818QC'd by Tocris
Activator13.206633.58140Complete curve; high efficacy-4.87922.78680.95467.0744100.6558-2.20 0 0 0 0 0 0 0 0 0 067.754798.655898.570696.727103.928498.9821101.4737101.0657104.952998.09980.670267.7547QC'd by Tocris
Inactive0-6.67921.88510.986131.798998.0488-1.20 0 0 0 0 0 0 0 0 0 025.841595.123897.430594.2779101.592396.623765.095439.564437.305231.26635.250725.8415QC'd by Tocris
Inactive6.61914.79230Complete curve; high efficacy; poor fit-5.17920.30.6009102.0708116.86340 0 0 0 0 0 0 0 0 0 0106.1195116.363115.8057116.9704115.3538109.6889110.0487117.1565112.8226108.1773109.0369106.1195QC'd by Tocris
Inactive0-5.62922.33320.99874.2257115.9211-1.10 0 0 0 0 0 0 0 0 0 04.4453114.2356114.2342113.7348116.5091116.1485116.8176115.75881.265818.57536.56294.4453QC'd by Tocris
Activator33.173498.53590Partial curve; high efficacy-4.47924.95490.977413.9975112.5334-30 0 0 0 0 0 0 0 0 0 030.1274105.5334110.0457106.7691113.3959114.4372114.0031116.163113.7765118.176111.260630.1274QC'd by Tocris
Activator14.81875.97180Complete curve; high efficacy-4.82921.10.955239.2664115.2383-2.20 0 0 0 0 0 0 0 0 0 054.2185115.5727106.9415117.026115.8501113.9337117.563115.9264111.494590.249382.203154.2185QC'd by SigmaAldrich
Inactive0-4.57924.0950.995718.2481117.382-2.10 0 0 0 0 0 0 0 0 0 027.2239118.8135117.2814121.5392116.8542117.5132118.0112115.2769115.261115.6537107.035927.2239QC'd by SigmaAldrich
Activator14.81886.11380Complete curve; high efficacy-4.82921.1110.958923.8777109.9915-2.20 0 0 0 0 0 0 0 0 0 037.4536105.3333114.29113.756113.3396109.4232110.8614101.71494.821793.122770.331637.4536QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ATLMIPE3+IL2
Protocol: Plate log growing ED40515 +IL2 cells: 1000cells/ well in 5uL phenol red free RPMI +5% FBS +1x p/s, Glutamine using 1536 well white griener tissue culture plates and multidrop cassette acoustic dispensing Columns 1 and 3 DMSO Columns 2 and 4, 9.2 uM Bortezomib Incubate 48 hours for celltiter glo 37C with 5%CO2 and 95% humidity with low evaporation lids Dispense 3 uL per well of cell titer glo with multidrop Incubate for 15 minutes at RT Read on VL/2 using Luminesence Wheel (Filter A)
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis.CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity.at.0.0003926931.uMActivity.at.0.0007804147.uMActivity.at.0.00118.uMActivity.at.0.00232.uMActivity.at.0.00353.uMActivity.at.0.00468.uMActivity.at.0.00703.uMActivity.at.0.014.uMActivity.at.0.021.uMActivity.at.0.041.uMActivity.at.0.063.uMActivity.at.0.122.uMActivity.at.0.190.uMActivity.at.0.286.uMActivity.at.0.563.uMActivity.at.0.859.uMActivity.at.1.138.uMActivity.at.1.709.uMActivity.at.3.373.uMActivity.at.5.124.uMActivity.at.9.921.uMActivity.at.15.37.uMActivity.at.29.76.uMActivity.at.46.08.uMActivity.at.92.17.uMCompound.QC
Inactive0-4.57924.0950.9352-4.3862109.5074-2.10 0 0 0 0 0 0 0 0 0 05.937111.276198.353898.465113.252123.8496113.3665116.477112.592598.103298.44475.937QC'd by NCGCChem
Activator11.770445.28410Complete curve; high efficacy; poor fit-4.92924.95490.88556.1472101.4313-1.20 0 0 0 0 0 0 0 0 0 056.357198.687592.6502106.630595.490294.1041106.3539102.5622111.4815105.959965.595456.3571QC'd by NCGCChem
Inactive5.25767.97140Complete curve; high efficacy; poor fit-5.27924.95490.5799104.8089112.780240 0 0 0 0 0 0 0 0 0 0105.5248109.2802112.5936110.549113.849117.326113.4703108.6243117.489109.2587103.8874105.5248QC'd by Tocris
Activator16.626139.44080Partial curve; high efficacy; poor fit-4.77920.90.833772.5703112.0111-2.40 0 0 0 0 0 0 0 0 0 082.5605112.5111113.4956121.1417105.0674108.5057109.272112.7382103.3768105.240693.276982.5605QC'd by Tocris
Activator18.654857.05480Partial curve; high efficacy; poor fit-4.72922.72020.899963.6367120.6915-2.41 0 0 0 0 0 0 0 0 0 063.653496.5211111.8303113.1657129.2213122.9369123.2908115.37127.3088120.0475103.085663.6534QC'd by Tocris
Inactive0-4.77921.62590.9244-4.5062101.4521-2.10 0 0 0 0 0 0 0 0 0 02.935895.9604109.347290.818396.3288112.7692106.4271105.139596.746976.817163.1662.9358QC'd by Tocris
Inactive23.48529.61730Partial curve; high efficacy; poor fit-4.62920.70.569577.4424107.059740 0 0 0 0 0 0 0 0 0 086.1287109.5597117.550399.314798.5473105.9971109.9309105.2971104.298895.095598.936886.1287QC'd by Tocris
Activator23.48540.27730Partial curve; high efficacy; poor fit-4.62924.0950.798470.4026110.68-30 0 0 0 0 0 0 0 0 0 072.5976106.6248107.3219106.4059115.6157118.5966121.4932104.4615104.329110.372104.730572.5976QC'd by Tocris
Inactive0-4.77921.62590.9516-1.0532101.6122-2.10 0 0 0 0 0 0 0 0 0 010.802795.4883102.657498.054496.0111102.9701106.3913108.3255107.318176.441959.171110.8027QC'd by Tocris
Inactive0-4.62924.0950.950.0268122.2908-2.10 0 0 0 0 0 0 0 0 0 08.9436120.4045128.2196116.7733115.0651128.2269134.6948123.3407129.3396106.379101.63778.9436QC'd by Tocris
Inactive0-5.82921.47810.99261.7631115.4684-1.10 0 0 0 0 0 0 0 0 0 01.3182112.5244119.0775108.1682115.9367114.8247116.753292.8547.152322.45684.44441.3182QC'd by Tocris
Activator37.221245.78450Partial curve; high efficacy; poor fit-4.42924.95490.481674.268120.0525-30 0 0 0 0 0 0 0 0 0 085.8579118.5757109.4542107.3883117.9387125.848136.3214108.9812134.8503111.2072131.475385.8579QC'd by Tocris
Activator13.206634.57660Complete curve; high efficacy; poor fit-4.87921.98870.690260.503995.0804-2.40 0 0 0 0 0 0 0 0 0 063.12288.712491.1763110.482689.317885.1688103.976494.995296.745690.02675.580963.122QC'd by Tocris
Inactive0-5.27920.30.832-12.560785.6461-2.10 0 0 0 0 0 0 0 0 0 04.54370.326480.935580.001380.152256.625754.024246.711746.535145.745940.54154.543QC'd by Tocris
Inactive23.48536.01210Partial curve; high efficacy; poor fit-4.62920.80.554368.7625104.774640 0 0 0 0 0 0 0 0 0 077.0979108.7746109.030991.967692.4091104.0549100.4498105.7138105.7176100.390190.28277.0979QC'd by Tocris
Inactive0-5.87922.24810.99221.965107.7516-1.10 0 0 0 0 0 0 0 0 0 02.155297.2575109.4244107.9741112.6201109.9896109.718390.79840.83624.01955.41162.1552QC'd by Tocris
Activator18.654855.1460Partial curve; high efficacy; poor fit-4.72924.95490.791554.9149110.061-2.20 0 0 0 0 0 0 0 0 0 055.537690.6652103.4115121.5092113.2141119.8898110.116116.6432105.3547108.730294.751955.5376QC'd by Tocris
Activator20.93143.03040Partial curve; high efficacy; poor fit-4.67920.90.64169.789112.8194-2.40 0 0 0 0 0 0 0 0 0 078.3524109.8194123.7532113.5651108.2166121.7676100.6265104.9798113.193497.726102.657478.3524QC'd by SigmaAldrich
Activator16.626162.08490Partial curve; high efficacy; poor fit-4.77923.1320.784156.6644118.7492-2.20 0 0 0 0 0 0 0 0 0 059.7172115.8345125.8537110.4091113.4045109.6999127.2107106.2518141.4232118.829990.611659.7172QC'd by SigmaAldrich
Inactive0-5.47920.70.9755-1.2029113.2151-1.10 0 0 0 0 0 0 0 0 0 016.2535112.1677112.6262120.9954107.728894.581597.4996.067169.109743.325527.309916.2535QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303830
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard Text Value
ActivityActive
ActivityActive
ActivityActive
ActivityActive
ActivityActive
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: P53600
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 16 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser, the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader. For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000043054 uM-Replicate_1Activity at 0.0000099513 uM-Replicate_1Activity at 0.0000394398 uM-Replicate_1Activity at 0.0000922287 uM-Replicate_1Activity at 0.0002147056 uM-Replicate_1Activity at 0.0004452702 uM-Replicate_1Activity at 0.00122 uM-Replicate_1Activity at 0.00376 uM-Replicate_1Activity at 0.00955 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.049 uM-Replicate_1Activity at 0.109 uM-Replicate_1Activity at 0.249 uM-Replicate_1Activity at 0.761 uM-Replicate_1Activity at 2.332 uM-Replicate_1Activity at 5.986 uM-Replicate_1Activity at 13.53 uM-Replicate_1Activity at 30.31 uM-Replicate_1Activity at 65.96 uM-Replicate_1Activity at 171.5 uM-Replicate_1Activity at 622.7 uM-Replicate_1Activity at 1320.0 uM-Replicate_1Activity at 2952.0 uM-Replicate_1Activity at 6600.0 uM-Replicate_1Activity at 14760.0 uM-Replicate_1Activity at 33000.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive000411.68960.1156-13.79419.96613.16310.7283-0.13048.42250.8152-0.10070.800321.2177-5.098911.6896QC'd by GVKInconclusive22.349231.210810Partial curve; partial efficacy; poor fit-4.65074.95490.8311
Inactive00044.1278-1.2132-0.531.1724-13.6008-15.8488-1.6086-19.5261-1.84034.6782.76125.28040.28044.1278QC'd by SequoiaInactive0
Inactive0004-9.80083.31944.9321-4.8812-12.78760.30429.0414-8.94990.223314.08858.8057-15.4411-4.9694-9.8008QC'd by TocrisInactive0
Inactive0004-1.97565.0865-1.7855-7.44442.244-1.822215.634118.165121.11031.735-10.98693.971310.803-1.9756QC'd by MicrosourceInactive0
Inactive00046.85951.21214.5834-1.147427.33062.48186.32539.01910.214520.70491.9499-9.1091-8.70446.8595QC'd by SIGMAInactive0
Inactive0-4.80072.09370.639333.4297-12.96840 0 0 0 0 0 0 0 0 0 0 1 0 0 025.4284-14.8066-9.0853-13.581-7.588-35.7992-8.9477-21.4634-0.5226-3.92488.5216-5.58437.506325.4284QC'd by MicrosourceInactive0
Inactive0004-15.007-3.1282-9.3591-0.59167.66516.92395.64735.12210.15582.5991-1.3526-6.47-0.785-15.007QC'd by MicrosourceInactive0
Inactive000424.0896-0.8446-9.61-6.08550.45112.491311.00488.98224.16252.593115.94870.8545-5.437324.0896QC'd by VitasInactive0
Inactive0004-17.67891.269819.24249.9274-7.42686.6741.6608-11.9547-6.5433-0.12947.7321-0.9298-3.0587-17.6789QC'd by SequoiaInactive0
Inactive0004-14.1816-14.82752.70742.3606-2.2355-4.2683-14.785-4.9866-14.55780.587-5.4301-8.78443.5884-14.1816QC'd by MicrosourceInactive0-9.20073.19250.6375
Inactive0004-1.2316-19.54044.6965-1.2942-1.67070.2407-15.5972-0.1313-8.4723-7.3738-1.20892.41540.8864-1.2316QC'd by SequoiaInactive0
Inactive00041.5567-5.753613.963810.2956-0.5580-1.68249.770620.988-2.01438.1577-7.9909-2.67841.5567QC'd by VitasInactive0
Inactive0-5.00071.96730.395926.0362-2.459340 0 0 0 0 0 0 0 0 1 0 0 0 0 10.23290.7504-0.0238-13.01490.91413.2757.6-0.817-14.514333.15894.5704-6.010126.66430.2329QC'd by VitasInactive0-7.85074.95490.3764
Inactive00040.4996-11.00798.4449-5.51661.0437-5.31884.2154-11.5318-0.68280.560410.3541-10.0764-3.39490.4996QC'd by SequoiaInactive0
Inactive0004-11.29821.6112-9.15080.0988-19.993-7.174916.2891-28.8965-0.2185-13.4455-15.182-7.4087.9797-11.2982QC'd by SIGMAInactive0
Cytotoxic0.001329.371420Complete curve; partial efficacy; poor fit-8.90074.95490.6762-1.930827.4406-1.40 0 0 0 0 0 0 0 0 0 0 0 0 0 02.084327.380322.2956-1.7991-14.5009-13.0557-1.27961.8292-4.68462.1858-2.80191.152812.67842.0843QC'd by MicrosourceInactive0
Cytotoxic22.349237.143520Single point of activity-4.65074.95490.6826-37.6249-0.4814-30 0 0 0 0 0 1 0 0 0 0 0 0 0 0-35.0886-10.0183-3.78480.92698.32995.971651.8329-7.9197-7.10119.7258-3.0119-1.82540.4137-35.0886QC'd by MicrosourceCytotoxic19.918841.056720Single point of activity-4.70074.50450.7845
Inactive0004-8.20534.878-0.8843.033-7.545116.823-9.3197.52683.3384-2.1505-2.9445-18.3014-0.1048-8.2053QC'd by SpecsInconclusive25.076243.037610Single point of activity-4.60074.95490.5622
Inactive000420.76650.814812.61279.9828-12.22150.44040.7956-15.56271.1625-6.82596.0669-0.0505-1.196720.7665QC'd by Prestwick Chemical; Inc.Inconclusive22.349234.562510Single point of activity-4.65074.0950.9286
Inconclusive8.897437.738210Single point of activity-5.05073.1320.718338.15130.413130 0 0 0 0 0 0 0 0 0 0 0 0 0 1-5.95941.40094.89037.6788-4.8095-4.8507-6.912-0.4163-7.58221.59434.88844.768442.6535-5.9594QC'd by MicrosourceInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303829
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard Text Value
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: P53MS958
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of rat liver microsomes (Molecular Toxicology, Boone, NC) at final concentration of 0.5 mg/mL and 1uL of B-Nicotinamide adenine dinucleotide 2'-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader. For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000043235 uM-Replicate_1Activity at 0.0000098296 uM-Replicate_1Activity at 0.0000380988 uM-Replicate_1Activity at 0.0000933477 uM-Replicate_1Activity at 0.0002146311 uM-Replicate_1Activity at 0.0004426192 uM-Replicate_1Activity at 0.00122 uM-Replicate_1Activity at 0.00372 uM-Replicate_1Activity at 0.00957 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.049 uM-Replicate_1Activity at 0.109 uM-Replicate_1Activity at 0.249 uM-Replicate_1Activity at 0.768 uM-Replicate_1Activity at 2.332 uM-Replicate_1Activity at 5.986 uM-Replicate_1Activity at 13.53 uM-Replicate_1Activity at 30.31 uM-Replicate_1Activity at 65.96 uM-Replicate_1Activity at 171.5 uM-Replicate_1Activity at 622.7 uM-Replicate_1Activity at 1320.0 uM-Replicate_1Activity at 2952.0 uM-Replicate_1Activity at 6600.0 uM-Replicate_1Activity at 14760.0 uM-Replicate_1Activity at 33000.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive000415.4129-0.3878-0.18645.37348.8557-0.29272.5035-10.205-0.2227.988-2.2891.52765.497915.4129QC'd by ACCInactive0
Inactive0-9.30074.95490.81131-17.707840 0 0 0 0 0 0 0 0 0 0 0 0 0 01.0149-13.08993.2756-1.32141.18321.8535-0.3978-0.4282.5506-0.24571.49181.68870.55861.0149QC'd by ACCInactive0
Inactive00040.0279-7.8342-1.89942.16960.5638-6.7392.6266-0.50970.73195.3764-7.7238-0.06747.02780.0279QC'd by ACCInactive0
Inactive00041.38786.287211.3346-1.35856.9465-2.58585.0519-2.5689.0021.6411-1.72927.00831.07741.3878QC'd by ACCInactive0-5.45072.40640.4602
Inactive0004-6.0549-14.8117-16.0755-3.9155-14.9771-10.937-32.5334-11.9531.4447-12.5843-18.1191-11.5121-10.2319-6.0549QC'd by RTIInactive0
Inactive0004-22.5649-3.3758-16.2168-4.5428-4.51510.1292-2.6754-23.201-8.3262-3.0518-1.1305-3.6383-2.6115-22.5649QC'd by RTIInactive0-8.59910.80.691
Inactive0004-0.2302-3.0733-11.95531.9394-0.062-0.7676-9.0695-1.09531.199-3.6509-10.3544-18.6262-9.6473-0.2302QC'd by RTIInactive0-4.20294.95490.345
Inactive0004-31.97-9.3562-1.8629-4.3936-8.3595-10.443-39.3827-2.50720.54372.3156-5.5145-4.9746-4.5578-31.97QC'd by RTIInactive0
Cytotoxic48.936540.016120Single point of activity-4.31044.95490.9076-41.0161-1-30 0 0 0 0 0 0 0 0 0 0 0 0 0 10.8752-0.1555-0.1471-0.86110.5088-1.62211.8567-5.5667-4.26740.6449-1.1659-1.471-37.97790.8752QC'd by RTIInactive0
Inactive0-4.4812.25260.6231-17.4881-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.1568-8.0428-0.62356.2346-0.9991-1.44871.2877-1.82882.3924-2.4336-0.4068-0.0819-10.8685-14.1568QC'd by RTIInactive0
Inactive0-4.15464.95490.3365-27.53820.41540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.24640.0979-1.09382.89261.68642.0417-11.5049-1.00074.87532.0771-10.214919.6036-0.4282-21.2464QC'd by RTIInactive0-4.35463.92950.4572
Cytotoxic1.909462.99420Single point of activity-5.71914.95490.8427-65.284-2.29-30 0 0 0 0 0 0 0 0 0 0 1 1 1 121.2448-4.4527-11.9693-0.7569-1.67770.0603-12.88981.4183.8556-64.004-3.125819.149730.660221.2448QC'd by RTIInconclusive26.970339.101610Partial curve; partial efficacy-4.56912.40640.8048
Inactive0-5.73594.95490.4398-11.70950.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-18.5079-13.1487-1.13453.01137.6647-1.76074.95091.42740.7821-7.5706-10.5531-11.2568-1.1121-18.5079QC'd by RTIInactive0-5.13593.990.4729
Inactive0-4.91744.95490.4007150.513840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-8.2124-6.4957-1.34376.24526.8209-1.5109-0.187612.48363.7645-4.0819-5.983812.929113.901-8.2124QC'd by RTIInactive0
Inactive0004-4.309910.7843-0.2327-5.32226.8375-6.64633.82231.011417.173-2.68034.8346-1.5527-1.3315-4.3099QC'd by RTIInactive0
Inactive0-4.78644.95490.4643-0.5-6.943640 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.3412-9.0513-3.5748-2.3634-8.2237-8.0106-6.3527-9.1377-10.7863-6.9009-9.556-4.63561.3663-2.3412QC'd by RTIInactive0
Inactive00043.8948-9.18-4.528-7.8262-5.28180.1213-2.8514-5.27810.14171.4481-10.28080.21445.40843.8948QC'd by RTIInactive0-4.27824.0450.5133
Inactive00040.9309-0.3627-0.7959-0.29194.6133-6.45136.07670.37295.22822.4365-0.3736-6.44071.19840.9309QC'd by RTIInactive0
Inactive00044.6175-2.446-2.97794.96498.591-3.7225-1.29327.6265.56985.46650.618212.56510.39614.6175QC'd by RTIInactive0
Inactive00041.16141.11370.8635-2.0253-1.3109-1.0103-7.7297-0.07730.3904-0.9231-0.2649-8.99091.4551.1614QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53MS482
Protocol: Please refer to other AIDs 1963578, 1963580, 720687, 720685, 720678 and 720681 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the p53 with rat microsomes agonist mode assay (AID 1963578), cell viability counter screen (AID 1963580), and auto fluorescence counter screens (AID 720687, 720685, 720678, and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inactiveinactive0inactive0inactive0active antagonist37.95478669-56.89862383inactiveRohm and Haas
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactivePfaltz-Bauer
inactiveinactive0inactive0inactive0inactive0inactiveRadian International
inactiveinactive0inactive0inactive0inconclusive antagonistinactiveSpectrum Chemical
inactiveinactive0inconclusive agonistinactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveBattelle Northwest
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inconclusive agonistinactive0inactiveSIGMA
inactiveinactive0inactive0inactive0active antagonist11.47389904-137.559426inactiveTCI
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inconclusiveinactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveShanghai Xingling
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303831
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard Text Value
ActivityActive
ActivityActive
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53344
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 16 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser, the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000043054 uM-Replicate_1W530-Activity at 0.0000099513 uM-Replicate_1W530-Activity at 0.0000394398 uM-Replicate_1W530-Activity at 0.0000922287 uM-Replicate_1W530-Activity at 0.0002147056 uM-Replicate_1W530-Activity at 0.0004452702 uM-Replicate_1W530-Activity at 0.00122 uM-Replicate_1W530-Activity at 0.00376 uM-Replicate_1W530-Activity at 0.00955 uM-Replicate_1W530-Activity at 0.022 uM-Replicate_1W530-Activity at 0.049 uM-Replicate_1W530-Activity at 0.109 uM-Replicate_1W530-Activity at 0.249 uM-Replicate_1W530-Activity at 0.761 uM-Replicate_1W530-Activity at 2.332 uM-Replicate_1W530-Activity at 5.986 uM-Replicate_1W530-Activity at 13.53 uM-Replicate_1W530-Activity at 30.31 uM-Replicate_1W530-Activity at 65.96 uM-Replicate_1W530-Activity at 171.5 uM-Replicate_1W530-Activity at 622.7 uM-Replicate_1W530-Activity at 1320.0 uM-Replicate_1W530-Activity at 2952.0 uM-Replicate_1W530-Activity at 6600.0 uM-Replicate_1W530-Activity at 14760.0 uM-Replicate_1W530-Activity at 33000.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-2.7054-0.742917.6324-5.7098-2.4442-8.8689-8.44923.85664.8951.316-4.2342-2.2173-1.3067-2.705410004-0.008
Inactive10004-9.2163-14.98060.5352-3.1889-1.87493.657-6.40320.83436.099515.97381.8503-6.6623-7.3549-9.2163100040.5551
Inconclusive15.82281.873510Partial curve; high efficacy-4.80071.46410.942883.86851.9952.11 0 0 0 0 0 0 0 0 0 0 0 0 0 063.7671-25.2350.72594.9823.8964-6.011-7.50423.0243-0.36318.58029.552814.338143.879163.767110-5.15071.41630.6697-11.5276040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.41
Inactive10004-7.60360.157-0.8011-9.9636-13.0521-10.3016-8.2965-19.3101-11.1767-1.8658-10.3506-0.2558-4.7484-7.6036100040.7786
Inactive10004-1.25980.187213.2885.11046.52950.1337-12.0409-9.16955.1910.756-5.7729-4.064311.1384-1.2598100040.0274
Inactive10-4.79910.60.5308-18.20022.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.66682.13790.73361.997911.88191.0068-5.4624-1.91134.135-9.1428-3.5388-7.7512-8.3149-12.6668100042.1474
Inactive100040.120.6216.73751.29862.96138.4418-20.9196-8.36372.5119-0.9643-3.05170.98720.45280.12100040.1505
Inactive10004-3.34154.8601-0.05933.13132.492711.5913-1.4902-13.7451.9094-3.61140.17755.8982-1.925-3.3415100040.1916
Inactive100044.68764.03720.43261.7117-5.36330.01244.09393.29011.8675-5.35829.301-3.3996-6.65394.687610004-0.8649
Inactive1000414.45021.1662-13.4728-0.06892.7591-5.585-15.2304-11.60378.2866-5.55088.036-4.6022-4.845814.450210004-3.7942
Inactive10-4.60461.1110.576731.0459-6.10640 0 0 0 0 0 0 0 0 0 0 0 0 0 026.6548-7.6451-2.6127-0.4371-10.6818-11.93260.5693-21.22510.609-17.09791.011613.89869.803426.654810004-1.0538
Inconclusive15.166545.683610Partial curve; partial efficacy-4.81910.60.775941.0698-4.61382.20 0 0 0 0 0 0 0 0 0 0 0 0 0 032.1055-2.8274-2.73911.8943-2.4675-16.4634-3.3416-2.31647.09830.338415.525617.156218.43332.1055100040.1046
Inactive10-4.68594.50450.56518-4.235840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.1259-0.5226-4.0178-6.8476-0.1323-11.918-14.7798-1.343-0.6951-0.0477-3.8234-0.157915.36455.125910004-0.8015
Inactive10004-2.57192.1271-15.6379-9.9458-0.0566-1.3009-10.3345-4.73090.7930.4322-6.21176.0155-0.1149-2.571910004-0.2737
Inactive10-4.429110.3508160.584740 0 0 0 0 0 0 0 0 0 0 0 0 0 014.03072.8758-1.4333-4.09618.1324-0.1788-1.8365-3.40460.96875.33925.74960.63436.788614.030710004-0.3011
Inactive10-5.88644.95490.460410-0.303340 0 0 0 0 0 0 0 0 0 0 0 0 0 014.81111.65651.78890.1435-7.595-1.069210.26810.1065-11.50277.37014.69215.95186.487814.811110004-6.6938
Inactive1000412.70575.94743.12190.9114-1.934610.27262.0269-12.6992-5.01885.3788-5.1369-2.868815.767612.705710004-1.5792
Inactive100048.0685-3.4653-4.85211.49384.676215.0539-6.5066-14.57680.9838-2.93245.02795.50265.54988.068510004-2.3647
Inactive100040.21273.5618-0.86484.668510.12697.869-0.11867.88796.91763.71724.3769.7145-1.76850.212710004-0.1916
Inactive1000415.68179.5665-3.95061.963.0139-1.30215.9929-15.24591.98272.56765.42287.37042.786215.681710004-3.34
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303826
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Text ValueStandard Units
16.14IC50=16140nM
46.8IC50=46800nM
6.41IC50=6410nM
11.17IC50=11170nM
8.06IC50=8060nM
4.03IC50=4030nM
17.79IC50=17790nM
11.3IC50=11300nM
7.59IC50=7590nM
10.44IC50=10440nM
IC50Not Determined
8.98IC50=8980nM
4.94IC50=4940nM
8.02IC50=8020nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:tumor suppressor p53 [Homo sapiens]
External ID: P53MS233
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of human liver microsomes (XenoTech, Kansas City, KS) at final concentration of 0.5 mg/mL and 1uL of Beta-Nicotinamide adenine dinucleotide 2-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000042859 uM-Replicate_1W530-Activity at 0.0000098296 uM-Replicate_1W530-Activity at 0.0000389118 uM-Replicate_1W530-Activity at 0.0000921325 uM-Replicate_1W530-Activity at 0.0002143310 uM-Replicate_1W530-Activity at 0.0004423865 uM-Replicate_1W530-Activity at 0.00121 uM-Replicate_1W530-Activity at 0.00372 uM-Replicate_1W530-Activity at 0.00955 uM-Replicate_1W530-Activity at 0.022 uM-Replicate_1W530-Activity at 0.049 uM-Replicate_1W530-Activity at 0.109 uM-Replicate_1W530-Activity at 0.249 uM-Replicate_1W530-Activity at 0.761 uM-Replicate_1W530-Activity at 2.332 uM-Replicate_1W530-Activity at 5.986 uM-Replicate_1W530-Activity at 13.53 uM-Replicate_1W530-Activity at 30.31 uM-Replicate_1W530-Activity at 65.96 uM-Replicate_1W530-Activity at 171.5 uM-Replicate_1W530-Activity at 622.7 uM-Replicate_1W530-Activity at 1320.0 uM-Replicate_1W530-Activity at 2952.0 uM-Replicate_1W530-Activity at 6600.0 uM-Replicate_1W530-Activity at 14760.0 uM-Replicate_1W530-Activity at 33000.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10-5.20073.990.3607-2.5677740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.945810.030110.74434.3442-5.05659.97422.951914.24288.764610.73796.49832.3813-4.5519-0.945810004.0000-0.4661
Inactive10-5.65074.95490.5456-1.9439840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.08469.49733.81968.4513-0.619110.36259.433713.778210.27034.69635.4408-1.6199-1.45995.084610004.00001.5918
Inactive10-5.55070.20.470118-0.201840 0 0 0 0 0 0 0 0 0 0 0 0 0 011.2543-1.00153.75646.89974.79742.8342.87626.5347.24690.758412.16298.90029.7511.254310004.0000-5.5377
Inactive100041.163-3.51611.707-1.8835-3.46991.9890.10351.2453-2.9592-3.6379-2.9446-1.8761-0.93791.16310004.00000.1358
Inconclusive1000416.859332.73635.020523.23553.332115.0249-2.90566.9949.49478.34391.2576-2.0333-2.290216.859310004.00009.1878
Inconclusive10004-2.1455-0.55639.41727.7352.03946.42493.62662.90958.6089-4.7033-4.009520.11873.2965-2.145510004.00007.8923
Inactive10004-3.66575.64289.1238-0.71545.00783.34610.6894.02219.965210.092117.6894-0.24811.5526-3.665710004.000014.7162
Inconclusive100044.2675-5.79323.71026.399110.69910.51886.8431-0.265818.58843.903414.16020.41198.98754.267510004.00006.5135
Inactive100049.866218.26245.804817.49314.15489.82548.16059.947216.279414.177417.85510.539517.09199.866210004.0000-5.4950
Inactive10004-5.329712.331.7312-5.499611.4558-3.72499.28072.31575.44163.66498.36633.099311.8517-5.329710004.0000-5.3240
Inconclusive70.04772.348410Partial curve; high efficacy; poor fit-4.15460.80.6385105.628933.28052.30 0 0 0 0 0 0 0 0 0 0 0 0 0 080.211934.473140.812939.568732.405624.682727.567430.391541.000332.340943.744858.28146.303280.211910004.0000-2.1350
Inconclusive19.093534.34910Partial curve; partial efficacy; poor fit-4.71914.95490.7411-28.10156.2475-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 11.53110.97148.54297.49310.6748-2.691-2.1743-2.26359.19559.26333.86910.8178-29.03671.53110-5.01914.95490.734118.5000-1.04734.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7941
Inactive10-5.33594.95490.4604141.095140 0 0 0 0 0 0 0 0 0 0 0 0 0 024.7756-3.87228.9743-3.24331.4147-5.33746.5468-1.04071.0629-0.639615.012312.85582.944224.775610004.00004.5021
Inactive100047.41038.87323.5826-6.8276-3.40045.10857.125.99217.88590.76615.2069-2.5857-2.38937.410310004.0000-2.5566
Inactive10004-1.2866-1.8663.79256.244.97715.953813.60749.92898.28548.214414.36688.1213-0.9202-1.286610004.0000-3.9577
Inconclusive1000423.99170.9944-3.96381.687221.14372.265812.972312.03323.94191.4937-3.1913.4-3.920623.991710004.00006.2522
Inactive10004-4.56660.7965-6.9681-2.20180.034-1.99810.8299-0.3127-3.4977-3.3230.25471.8446-8.8778-4.566610004.00002.4663
Inactive10-7.02153.51170.347180.303440 0 0 0 0 0 0 0 0 0 0 0 0 0 010.5722-4.18564.19643.9575-4.3305-3.43177.7017.906311.39089.358710.9552-1.394.103110.572210004.00001.0750
Inactive10004-3.64221.972216.7669-4.364-3.7771-2.02811.2212-1.9042-4.0395-1.3596-5.395-2.4515-3.7855-3.642210004.00004.9536
Inactive1000416.4401-5.27783.8363-0.299718.8033-3.88715.63613.536316.4656.73621.28493.68095.811416.440110004.00004.3898
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4303825
Protocol: N/A
Comment: Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard Value
Selectivity index=1.11
Selectivity index=9.61
Selectivity index=4.53
Selectivity index>9.52
Selectivity index>>5.43
Selectivity index=2.61
Selectivity index=3.78
Selectivity index>>3.62
Selectivity index=4.3
Selectivity index>5.27
Selectivity index>4.62
Selectivity index=3.15
Selectivity index=13.31
Selectivity index>16.37
Selectivity index=2.59
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4303828
Protocol: N/A
Comment: Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard Value
Selectivity index=4.23
Selectivity index=5.71
Selectivity index=3.31
Selectivity index>5.8
Selectivity index>>4.48
Selectivity index=2.3
Selectivity index=2.94
Selectivity index>>2.81
Selectivity index=1.81
Selectivity index>3.91
Selectivity index>4.08
Selectivity index=2.23
Selectivity index=6.97
Selectivity index>6.84
Selectivity index=2.29
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: P53MS837
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of human liver microsomes (XenoTech, Kansas City, KS) at final concentration of 0.5 mg/mL and 1uL of B-Nicotinamide adenine dinucleotide 2'-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader. For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000042859 uM-Replicate_1Activity at 0.0000098296 uM-Replicate_1Activity at 0.0000389118 uM-Replicate_1Activity at 0.0000921325 uM-Replicate_1Activity at 0.0002143310 uM-Replicate_1Activity at 0.0004423865 uM-Replicate_1Activity at 0.00121 uM-Replicate_1Activity at 0.00372 uM-Replicate_1Activity at 0.00955 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.049 uM-Replicate_1Activity at 0.109 uM-Replicate_1Activity at 0.249 uM-Replicate_1Activity at 0.761 uM-Replicate_1Activity at 2.332 uM-Replicate_1Activity at 5.986 uM-Replicate_1Activity at 13.53 uM-Replicate_1Activity at 30.31 uM-Replicate_1Activity at 65.96 uM-Replicate_1Activity at 171.5 uM-Replicate_1Activity at 622.7 uM-Replicate_1Activity at 1320.0 uM-Replicate_1Activity at 2952.0 uM-Replicate_1Activity at 6600.0 uM-Replicate_1Activity at 14760.0 uM-Replicate_1Activity at 33000.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-0.81153.24171.7036-3.88633.70051.90923.46112.62383.42171.96184.5532-2.1817-2.0587-0.8115QC'd by SIGMAInactive0
Inactive00042.02641.27780.40633.132-0.96178.39740.80260.38625.08541.03870.96490.31392.19092.0264QC'd by Sigma DiscoveryCPRInactive0-6.03963.990.6227
Inactive0004-0.07830.8602-0.43130.77533.3389-7.07430.1475-4.9244-5.6061.28811.431-5.9165-1.58613.3747-0.0783QC'd by SIGMAInactive0-4.85182.12110.4048
Inactive0-8.53960.90.4382.5-17.2540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.4242-11.5665-3.6679-0.6129-7.17834.78830.4184-0.157710.703511.6402-3.9345-0.5512-6.24530.4242QC'd by SIGMAInactive0-7.93964.95490.4551
Inactive0004-5.3318-1.94410.4522-8.3321.0107-0.1156-10.7826-10.8532-4.24710.20287.2076-6.6671-8.3789-5.3318QC'd by SIGMAInactive0
Inactive00040.6118-3.3835-2.5203-9.6183-0.5168-7.3565-1.9351-3.59144.7435-5.2628-2.1247-4.3417-14.53680.6118QC'd by SIGMAInactive0
Inactive0004-5.3821-1.5125-3.5484-1.106-5.2777-3.6383-5.511-10.9006-6.9604-1.92230.6192-4.5677-4.7296-8.0223QC'd by SIGMAInactive0-8.2680.30.4015
Inactive00040.87320.4702-0.8794-0.6340.6861-1.04133.7723-12.8167-6.05652.7542-1.535-7.9041-5.49780.8732QC'd by SIGMAInactive0
Inactive0-6.83964.95490.55124-4.470340 0 0 0 0 0 0 0 0 0 0 0 0 0 01.0676-1.3224-9.1419-1.1865-3.6159-5.2485-8.195310.19175.79951.09081.49983.96712.02971.0676QC'd by SIGMAInactive0-6.78964.95490.3599
Inactive0004-1.0220.210.2513-2.37471.3717-0.50383.9894-1.7888-6.79872.53691.01664.19945.5844-1.022QC'd by SIGMAInactive0-6.38964.95490.3471
Inactive0004-1.4059-3.132-7.66070.7238-4.33320.32411.33020.24797.5234-14.4771-13.01446.36361.2275-1.4059QC'd by RocheInactive0
Inactive0-4.33964.95490.3429-10.88620.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.07183.4287-0.5118-4.4669-2.302-2.17713.30782.8439-1.01244.2267-6.21353.9872-0.6916-9.0718QC'd by TCIInactive0
Inactive0004-0.68310.0297-0.9593-0.7386-2.2052-1.3291-4.3626-5.62091.9907011.30340.7086-3.1047-0.6831QC'd by SIGMAInactive0-5.48964.95490.3751
Inactive0-5.93961.78850.35820-3.229640 0 0 0 0 0 0 0 0 0 0 0 0 0 00.3463-2.7679-2.538-3.6541-2.975-8.1080.403-4.8358-1.7099-1.45512.2456-0.5792-0.4960.3463QC'd by SIGMAInactive0
Inactive0004-11.95511.4361-7.8259-8.6263-1.52171.5909-12.8729-11.017-6.8916-3.5531-4.5898-4.7446-6.1302-11.9551QC'd by LightBiologicalsInactive0
Inactive0004-9.9242-1.6531-3.70011.0424-7.9893.6152-5.8328-1.3701-2.0464-3.8438-5.7091-2.1285-5.1644-9.9242QC'd by SIGMAInactive0-4.33963.67720.3682
Cytotoxic40.77972.441840Partial curve; high efficacy-4.38963.92950.8982-74.5596-2.1178-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-64.8179-2.60644.2761-5.9881-1.3877-6.5057-2.59266.3601-8.70221.2883-0.5997-1.9403-18.4593-64.8179QC'd by TCICytotoxic51.337734.492820Single point of activity-4.28964.95490.8014
Inactive0004-14.5026-3.1743.642-4.3769-9.3023-7.6508-8.2832-19.8532-7.861711.7122-6.9451-14.94643.8797-14.5026QC'd by SIGMAInactive0
Inactive0004-2.2222-0.98421.4931-1.41171.1017-10.6336-4.34-12.0027-8.0387-2.805-8.872512.3039-3.6772-2.2222QC'd by SIGMAInactive0
Inactive0-7.33964.95490.52824.5-2.771840 0 0 0 0 0 0 0 0 0 0 0 0 0 01.0674-3.5855-4.2141.2009-4.39320.913.422214.0382.72535.26962.21886.31271.41211.0674QC'd by RocheInactive0-4.73964.0950.6096
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Vero C1008
External ID: CHEMBL4303827
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL4303840
ChEMBL Target Name: Vero C1008
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
41.46CC50=41460nM
50CC50>50000nM
21.21CC50=21210nM
50CC50>>50000nM
18.53CC50=18530nM
11.88CC50=11880nM
50CC50>>50000nM
20.51CC50=20510nM
29.68CC50>29680nM
42.59CC50>42590nM
0.39CC50<390nM
20.02CC50=20020nM
34.42CC50=34420nM
18.37CC50=18370nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:tumor suppressor p53 [Homo sapiens]
External ID: P53MS898
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of rat liver microsomes (Molecular Toxicology, Boone, NC) at final concentration of 0.5 mg/mL and 1uL of Beta-Nicotinamide adenine dinucleotide 2-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000043397 uM-Replicate_1W530-Activity at 0.0000099416 uM-Replicate_1W530-Activity at 0.0000388206 uM-Replicate_1W530-Activity at 0.0000933245 uM-Replicate_1W530-Activity at 0.0002146562 uM-Replicate_1W530-Activity at 0.0004427766 uM-Replicate_1W530-Activity at 0.00122 uM-Replicate_1W530-Activity at 0.00372 uM-Replicate_1W530-Activity at 0.00957 uM-Replicate_1W530-Activity at 0.022 uM-Replicate_1W530-Activity at 0.049 uM-Replicate_1W530-Activity at 0.109 uM-Replicate_1W530-Activity at 0.249 uM-Replicate_1W530-Activity at 0.768 uM-Replicate_1W530-Activity at 2.332 uM-Replicate_1W530-Activity at 5.987 uM-Replicate_1W530-Activity at 13.55 uM-Replicate_1W530-Activity at 30.33 uM-Replicate_1W530-Activity at 65.98 uM-Replicate_1W530-Activity at 172.8 uM-Replicate_1W530-Activity at 616.1 uM-Replicate_1W530-Activity at 1320.0 uM-Replicate_1W530-Activity at 2952.0 uM-Replicate_1W530-Activity at 6600.0 uM-Replicate_1W530-Activity at 14760.0 uM-Replicate_1W530-Activity at 33000.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-0.0766-0.0658-2.15293.9062-0.3999-1.37385.63961.2637-2.85641.76041.55167.3112-1.1534-0.076610004.0000-0.5396
Inactive10004-9.26574.0277-6.0118-0.0071-1.8112.0788-0.1063-9.81183.02231.6158-3.4131-0.3905-0.1348-9.265710004.0000-0.7395
Inconclusive17.752636.150110Partial curve; partial efficacy-4.75072.40640.95137.51.34992.20 0 0 0 0 0 0 0 0 0 0 0 0 0 030.754-1.3751.59181.76342.18881.4238-0.72522.56751.81642.88342.28283.111216.001330.75410-4.70072.40640.9040-16.0184-1.00004.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.5153
Inactive10004-0.8668-1.48543.1589-1.5267-0.3498-0.9828-1.6965-4.30540.34461.0195-3.8892-0.0431-3.4971-0.866810004.00002.1550
Inactive100040.4687-0.3692-2.2383-2.0699-1.1088-1.1038-1.892-3.7217-0.3761-2.9675-7.199-1.25980.5490.468710004.0000-4.3810
Inactive100040.4126-1.2865-0.5387-2.298-1.8546-1.5264-1.5856-1.7954-2.1107-10.0252-3.0851-2.8249-1.38430.412610004.00000.0966
Inactive10-8.75291.53860.542-3.90151040 0 0 0 0 0 0 0 0 0 0 0 0 0 10.10826.8455-0.6219-1.9403-3.2657-2.4784-1.636-6.3641-2.7947-6.0758-3.8759-3.1216-2.63750.108210004.0000-1.7240
Inactive10004-2.64841.2797-2.7761-6.4353-4.779-1.4021-0.3446-1.6237-1.1309-5.3966-0.90140-0.5502-2.648410004.00004.8834
Inactive10004-0.1792-0.474-1.4694-0.8953-0.4709-0.74150.1743-4.2804-1.4515-8.5725-1.40966.8573-0.4899-0.179210004.00000.3507
Inactive10-5.2314.95490.63782.5-6.309340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.5172-6.7601-8.0367-0.7524-8.9539-6.7515-6.0875-9.8411-8.2478-4.204-0.20621.74341.04493.517210004.00007.8280
Inactive10-5.25464.95490.73888-2.536240 0 0 0 0 0 0 0 0 0 0 0 0 0 011.2916-1.1337-0.9738-3.7502-3.5438-3.92812.0571-0.3539-3.0856-2.45181.10275.54624.50711.291610004.00000.2257
Inactive10-4.71910.80.3767-22.1814-240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.9565-2.4609-4.7653-0.7909-4.3968-2.1758-2.0522-3.5012-2.3448-13.94742.318-16.8178-12.5058-7.956510004.0000-0.5576
Inactive10-5.38594.95490.609313-3.112140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.9382-2.1013-5.1202-0.9168-6.4291-0.2473-7.5114-1.6150.7413-1.600515.74921.42750.7564-0.938210004.00003.5229
Inactive10004-2.5193-0.5943-0.7208-2.3194-2.31182.0984-4.0928-2.1388-3.1827-4.05230.0794-0.2907-0.4065-2.519310004.00002.1690
Inactive10-4.97912.72020.55856-4.095340 0 0 0 0 0 0 0 0 0 0 0 0 0 08.8855-0.6587-4.6588-0.4651-5.4882-3.2508-2.652-4.0762-6.6845-6.0914-4.67266.54320.29268.885510004.00008.4566
Inactive100040.3919-1.19260.06151.2782-3.2151-0.8299-0.6638-3.5934-2.2676-3.964912.1718-12.289-2.3960.391910-4.28643.13200.766711.50000.55584.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 08.8922
Inactive100041.3115-1.013-0.5151-0.4031-1.1603-0.0285-0.1807-1.90091.5472-3.20528.574-14.1104-2.36981.311510004.00000.7374
Inactive100041.2453-0.1374-0.3605-3.4935-1.2563-2.4487-0.2616-0.72990.0304-4.47-0.75345.7775-0.09731.245310004.00001.2743
Inactive100040.0274-0.9052-3.7849-3.6459-0.6677-0.01462.1795-6.8978-0.8919-5.2845-0.8362-13.15210.1420.027410004.0000-2.5213
Inactive10004-2.4878-3.5001-2.6738-5.3379-5.5521-3.88740.4423-5.0105-3.9092-8.9672-0.5005-7.892-0.4544-2.487810004.00000.0360
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4303822
Protocol: N/A
Comment: Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard Value
Selectivity index>7.4
Selectivity index>19
Selectivity index>2.35
Selectivity index>1.13
Selectivity index>10
Selectivity index>2
Selectivity index>3.7
Selectivity index>1.7
Selectivity index>1.8
Selectivity index>7.8
Selectivity index>7.9
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: OBG420
Protocol: Assay Protocol Summary:

1,000 cells in 4 uL of media were dispensed into white, solid bottom 1536-well plates using a Multidrop Combi (Thermo Scientific). The Assay plates were incubated for 16 hours at 37 C with 5% CO2 in assay plates, followed by the addition of 23 nL of DMSO or drug dissolved in DMSO. Each compound was assayed in five concentrations (0.092, 0.46, 2.3, 11.5, and 57.5 uM), using the automated Wako 1536 Pin Tool workstation and incubated at 37 C with 5% CO2 48 hours. 4 uL of ATPlite, the ATP monitoring reagent, was then added to the each well of the assay plates using the Multidrop Combi reagent dispenser followed by incubation for 15 minutes at room temperature. The resulting luminescence was measured using the ViewLux plate reader.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, cytotoxic compounds are considered active and show up as apparent inhibitors, which are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002299000 uMActivity at 0.0009353959 uMActivity at 0.00184 uMActivity at 0.00468 uMActivity at 0.00919 uMActivity at 0.016 uMActivity at 0.027 uMActivity at 0.051 uMActivity at 0.092 uMActivity at 0.155 uMActivity at 0.256 uMActivity at 0.462 uMActivity at 0.846 uMActivity at 1.283 uMActivity at 2.310 uMActivity at 4.246 uMActivity at 6.551 uMActivity at 11.58 uMActivity at 25.26 uMActivity at 38.52 uMActivity at 57.54 uMActivity at 116.1 uMActivity at 221.6 uMActivity at 288.3 uMPanel IDPanel Name
Inactive0.089120.43770-7.054.95490.524316-4.437740 0 0 0 013.1195-1.614723.02214.923222.436413.11953PA-1
Inactive0.501219.5120-6.34.50450.98372.5-17.01240 0 0 0 04.6148-17.0933-15.1392.02030.96314.61484SKOV3
Inactive0.089110.17840-7.054.95490.4664-7.67842.540 0 0 0 0-7.22470.9983-11.3986-10.48-0.961-7.22475C33A
Inactive000046.8018-1.79437.92887.71697.15576.80186JEG-3
Inactive0.6315.87540-6.24.95490.65335-0.875440 0 0 0 04.99780.7404-1.97958.09512.36074.99787Es-2
Inactive00004-1.56592.9339-4.8958-4.79511.5969-1.56598Hek293T
Inactive0.08919.9950-7.054.95490.3786-7.4952.540 0 0 0 0-5.41281.1477-11.5205-0.3743-12.9125-5.41289Tov112D
Inactive00004-3.29573.83081.4062-4.436-2.7163-3.295710Tov-21-G
Inactive0.707914.66040-6.154.95490.999411.5-3.160440 0 0 0 11.8313-3.0503-3.035511.111111.20241.831311OV90
Inactive2.511911.03920-5.61.62590.99184.5-6.539240 0 0 0 04.3244-5.7563-6.6993-3.04413.02174.324412CASKI
Inactive000044.00029.26091.730716.16898.27064.00021CAOV3
Inactive0.112.42240-71.64360.8881-1.922410.540 0 0 0 0-4.51867.76070.4819-0.6217-0.7957-4.51862HeLa
Inactive000049.02713.25131.741213.527517.68579.0273PA-1
Inactive0.3162180-6.54.44950.963772540 0 0 0 119.687125.203421.51315.01739.427119.68714SKOV3
Inactive000040.33690.4452-0.91255.72924.440.33695C33A
Inactive0.063110.50-7.24.95490.8451212.540 0 0 0 01.087910.83860.19022.46194.63951.08796JEG-3
Inactive0.50129.55980-6.34.95490.95170-9.559840 0 0 0 0-0.0179-8.4158-10.46650.9667-1.2439-0.01797Es-2
Inactive0.063114.81190-7.24.95490.534-5.8119940 0 0 0 10.28146.5861-12.75991.4268-6.08970.28148Hek293T
Inactive8.91258.5410-5.054.0450.6148-0.54140 0 0 0 07.75193.7595-4.2009-0.57340.66357.75199Tov112D
Inactive000041.0625-0.46660.2533-1.2691-7.13331.062510Tov-21-G
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Vero C1008
External ID: CHEMBL4303821
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303840
ChEMBL Target Name: Vero C1008
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
40CC50>40000nM
40CC50>40000nM
40CC50>40000nM
40CC50>40000nM
40CC50>40000nM
40CC50>40000nM
40CC50>40000nM
40CC50>40000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: HERG01
Protocol: NCGC Assay Protocol Summary:

HERG assay (FluxORTM thallium flux assay) was initially developed by Invitrogen/Molecular Probes, and then miniaturized into 1536-well plate in a homogeneous format by NCGC. This assay measures the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells with a FDSS-7000 kinetic plate reader (Hamamatsu Corp., Hamamatsu City, Japan). The hERG ion channel is transduced into mammalian cells (U2OS) using a baculovirus (Bacmam) construct harboring the hERG K+ ion channel. So far we screened LOPAC1280 library (Sigma), the NTP collection of 1408 compounds, and the NCGC Pharmaceutical Collection (NPC), in which many well defined HERG blockers are present. The rank order potencies of many of these compounds are similar to that of other HERG assays (membrane potential, Rb+ flux, patch clamp, etc). This quick and homogeneous assay is also found to be sensitive, specific, and robust.

Using the FluxORTM thallium flux assay, the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells was measured in the U2OS cell line transduced with hERG K+ ion channel using a baculovirus (Bacmam) using Opti-MEM medium (Invitrogen) containing 2% fetal calf serum (FCS, HyCone) following loading buffer addition, compound treatment for around 10 minutes and finally adding stimulation buffer. The assay was performed in black clear Kalypsys 1536-well plates. In the screen, Astemizole was used as positive controls. Library compounds were measured for their ability to cause hERG channel blockage in the cell line, as reflected by a decrease in fluorescence intensity, in a concentration-dependent manner. Data were normalized to the controls for basal activity (DMSO only) and 100% inhibition (5uM Astemizole). AC50 values were determined from concentration-response data modeled with the standard Hill equation.

qHTS protocol for hERG-U2OS cellular assay

[Step] [Parameter] [Value] [Description]

1. Day 1: Replace medium in 70-80% confluent T225 flask with 2.5 mL of hERG-BacMam virus plus 12.5 mL of phosphate buffered saline (PBS) (corresponding roughly to a multiplicity of infection ratio of 100 virus particles/cell)
2. Incubation: 4 hrs @ room Temperature in Dark
3. Reagent; Remove virus; wash once with 25 ml DPBS
4. Reagent; 35 ml culture medium
5. Incubation; 37oC overnight
6. Day2: Reagent; 3 uL; 2000 U2OS cells/well
7. Time; 4 hr; 37oC incubation
8. Loading buffer; 1 uL; 0.7X;
9. Incubation: 1hr @ RT in Dark.
10. Compounds; 23 nL; 0.59 nM to 92 uM
11. Controls; 23 nL; Astemizole 1.4 nM to 92 uM
12. Time; 10min; 37oC incubation
13. Read fluorescence Intensity on FDSS for 10 Sec with 1 sec interval
14. Reagent; 1 uL; stimulation buffer
15. Read fluorescence Intensity on FDSS for 2 min with 1 sec interval
16. Detection; Fluorescence Intensity; FDSS
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001000000 uMActivity at 0.0003000000 uMActivity at 0.0006116734 uMActivity at 0.00133 uMActivity at 0.00297 uMActivity at 0.00673 uMActivity at 0.015 uMActivity at 0.033 uMActivity at 0.075 uMActivity at 0.167 uMActivity at 0.369 uMActivity at 0.412 uMActivity at 0.836 uMActivity at 1.842 uMActivity at 2.061 uMActivity at 4.179 uMActivity at 9.216 uMActivity at 20.61 uMActivity at 46.08 uMActivity at 92.17 uMCompound QC
Inactive04.0950.5622-0.5-17.405541 0 0 0 0 0 1 0 0 0 0 0 0 04.0358-8.1088-16.5879-0.7265-5.65844.3730.1327-9.70320.36854.1527-0.141-3.5272-0.9713-9.32034.0358QC'd by NIEHS/NTP
Activator15.848952.39750Single point of activity-4.80.40.510848.9806-3.416930 0 0 0 0 1 0 0 0 0 0 1 0 1 038.06212.0116-8.9739-7.06230-7.0944-39.2396018.733825.780800-59.539411.623748.215338.0621QC'd by NIEHS
Inactive04-1.0832-10.89741.0031-11.058-11.8883.65680.91825.31740.029-1.48932.17113.0788-19.8367-2.8584-1.0832QC'd by NIEHS/NTP
Inactive042.45982.223-1.63678.778-0.11389.22693.440711.6742-2.146511.8823-1.8078-2.0833.78254.49092.4598QC'd by NIEHS
Inactive01.85790.45754.5-21.089940 0 0 0 0 0 0 0 0 0 0 0 0 012.886-15.90830.10180.3771-0.02467.9993-3.79713.097311.63728.3022-2.66639.3202-2.3421-0.285412.886QC'd by NIEHS/NTP
Inactive04.95490.5492-6.77071.540 0 0 0 0 0 0 0 0 0 1 0 0 11.3669-1.0856-0.77651.12421.70580.7901-1.98696.09015.26593.2331-7.9279-28.3694-1.3017-10.22551.3669QC'd by NIEHS/NTP
Inactive04-5.5826-4.0359-4.4476-11.3473-11.9097-1.5507-10.1535-3.36261.3234-0.4426-13.9824-5.2512-18.0387-15.3022-5.5826QC'd by NIEHS/NTP
Inhibitor39.810751.900420Partial curve; partial efficacy-4.43.990.9828-50.13811.7623-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0-49.45943.1993-0.02692.7134-1.98075.29460.2133-0.1387-0.26252.47080.17772.53720.4925-30.4729-49.4594QC'd by NIEHS/NTP
Inactive02.33320.6977-10.8456140 0 0 0 0 0 1 0 0 0 0 1 0 1-1.1266-1.46111.2528-0.03690.02955.5889-3.03576.75064.5747-1.4797-0.1821-9.6414-1.4402-9.8713-1.1266QC'd by NIEHS/NTP
Inactive0414.60080.5397-1.6708-0.4130.96947.4259-2.25855.08697.9351-2.4752-5.6365.39961.849-2.487114.6008QC'd by NIEHS/NTP
Inactive00.70.5791-8.9231440 0 0 0 0 0 1 0 0 0 0 0 0 12.80633.51535.19381.41166.33634.612.742912.44016.0481-0.14110.3707-1.47812.4968-5.76932.8063QC'd by NIEHS/NTP
Inactive04-17.8369-10.5115-2.5586-8.8158-26.0957-0.4819-9.7892-2.01490.27332.7166-17.2183-0.47591.0932-12.7028-17.8369QC'd by NIEHS/NTP
Inactive04.95490.4427-9.7222-1.541 0 1 0 0 0 0 0 0 0 0 0 0 0-13.1018-5.53920.00687.73370.45884.0455-12.3759-6.57240.92181.9145-11.3469-7.6261-8.5179-8.6226-13.1018QC'd by NIEHS/NTP
Inactive03.1320.7434-16.07841.540 0 0 0 0 0 0 0 0 0 0 0 0 13.99653.3921-1.15561.97152.01773.8894-2.6092.87572.72384.1025-3.54462.1635-3.6983-12.9823.9965QC'd by NIEHS/NTP
Inactive047.53724.3881-20.20115.5178-1.37582.0045-1.44014.9593-2.11221.3726-3.0011-3.06771.18832.18177.5372QC'd by NIEHS/NTP
Inactive0411.45250.2692-0.1403-0.3748-11.74892.8347-5.054616.89840.0513.829-3.6094-0.51978.0326-1.547611.4525QC'd by NIEHS/NTP
Inactive049.99361.71397.16916.3352-0.34329.148-5.8673-1.564112.6111.82378.2616-0.66541.73632.63199.9936QC'd by NIEHS/NTP
Inactive0410.2340.52521.3877-1.9626-0.9425.6494-0.276911.70528.3766.8657-0.149-0.19442.6788-6.419210.234QC'd by NIEHS/NTP
Activator22.387233.89380Complete curve; partial efficacy; poor fit-4.652.25260.715133.99630.10251.40 0 0 0 0 0 0 0 0 0 0 0 0 025.52240.4272-0.9219-0.128-2.10618.1765-1.5863-10.226512.16486.8628-0.3193-6.515517.608732.268925.5224QC'd by NIEHS/NTP
Inactive049.98485.58260.0396-1.5504-1.30043.2953.988212.27428.06469.11922.031.29227.4225-2.99749.9848QC'd by NIEHS/NTP
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23209 靶标:N/A
External ID: UIHTS20180925
Protocol: Assay overview:
The purpose of this assay is to identify test compounds that differentially kill either epithelial cells or mesenchymal cells, critical components of EMT. The PC-3E+ and TEM4-18 cell lines, characterized as epithelial cells and mesenchymal cells respectively, were established in Henry Lab (Ref 1). For potential discriminative modulators of EMT, the two cells lines were labeled with GFP and mCherry respectively, and co-cultured together to eliminate those hits that non-discriminatingly kill both epithelial cells and mesenchymal cells by cytotoxicity irrelevant to the EMT properties.
Protocol for the EMT project:
The primary screening data were generated as described in HTS assay protocol table (Ref 2).

Table 1: HTS assay protocol table
Step Parameter Value Description
1. Plate cells 200 uL By MultiFlo. PC3E GFP 2,000 cells/ well and TEM418 mCherry 2,000 cells/well (1:1). Overnight incubation
2. Remove media Flip the plate
3. Add fresh media 150 uL By MultiFlo
4. Controls 200 uL C01-H01, C12 -H12, Hygromycin dose response from H to C were positive control. Wells A01, B01, A12 and B12 were negative control
5. Library 50 uL MSSP library 1 uM final from middle plate in full media
6. Incubation 72 hrs 37 C and 5% CO2
7. Assay readout GFP and mCherry channel imaging Perkin Elmer Operetta high content imaging system, with Harmony image analysis software.
8. Image analysis Green cells and Read cells counting Normalized to the average cell number of well B1 and B12 (no inhibition of cell viability) controls on each plate to get relative cell viability for each well.
9. Hit selection 11 hits The hit criteria for preferential cell killing are compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal
0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing OR Greencells_Normalized is
lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent
by itself for Green cell killing.

The primary screening data (imaging data) were translated into Green or Red cell numbers in each well in the data file.
Comment: Preferential killing compounds are considered as active hits (score of 100) when meeting one of two groups of criteria:

1. Compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal 0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing.

OR

2. Greencells_Normalized is lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent by itself for Green cell killing.
No. of GreenCellsNo. of RedCellsGreenCells_NormalizedRedCells_NormalizedRedCells/GreenCells_Normalized
178911800.881.081.22
196110810.970.991.02
187612910.931.181.27
224410941.1110.9
227512101.121.110.98
199513980.981.281.3
212312931.051.181.13
228112271.131.121
196410900.9711.03
211012951.041.181.14
234213611.161.241.08
201413160.991.21.21
2021127011.161.16
216012871.071.181.1
2022119711.091.1
179810820.890.991.11
193811991.081.060.98
200012601.121.110.99
197112011.11.060.96
210011301.1710.85
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303805
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=-11.52%Outside typical range
Inhibition=5.09%
Inhibition=-1.71%
Inhibition=3.69%
Inhibition=22.47%
Inhibition=8.51%
Inhibition=-6.86%
Inhibition=-6.18%
Inhibition=-2.07%
Inhibition=3.91%
Inhibition=-5.9%
Inhibition=-2.45%
Inhibition=-5.55%
Inhibition=6.31%
Inhibition=-1.08%
Inhibition=12.7%
Inhibition=0.37%
Inhibition=8.88%
Inhibition=11.63%
Inhibition=-1.96%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303820
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
8.65EC90=8.65uM
40EC50>40000nM
40EC50>40000nM
17.06EC50=17060nM
38.01EC90=38.01uM
35.37EC50=35370nM
45.11EC90=45.11uM
4.17EC50=4170nM
25.49EC90=25.49uM
40EC50>40000nM
20.22EC50=20220nM
40EC90>40uM
40EC50>40000nM
40EC50>40000nM
10.7EC50=10700nM
15.2EC90=15.2uM
23.94EC50=23940nM
38.23EC90=38.23uM
22.04EC50=22040nM
42.81EC90=42.81uM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303819
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard Value
Inhibition index=0.1602
Inhibition index=0.05118
Inhibition index=0.4224
Inhibition index=0.0165
Inhibition index=0.2502
Inhibition index=0.07412
Inhibition index=0.07718
Inhibition index=-0.01621
Inhibition index=0.222
Inhibition index=0.4759
Inhibition index=0.2023
Inhibition index=0.02609
Inhibition index=0.646
Inhibition index=0.2499
Inhibition index=2.099
Inhibition index=0.3518
Inhibition index=0.04502
Inhibition index=0.1687
Inhibition index=0.0604
Inhibition index=0.09117
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Vero C1008
External ID: CHEMBL4303824
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL4303840
ChEMBL Target Name: Vero C1008
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
41.46CC50=41460nM
50CC50>50000nM
21.21CC50=21210nM
50CC50>>50000nM
18.53CC50=18530nM
11.88CC50=11880nM
50CC50>>50000nM
20.51CC50=20510nM
29.68CC50>29680nM
42.59CC50>42590nM
0.39CC50<390nM
20.02CC50=20020nM
34.42CC50=34420nM
18.37CC50=18370nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303823
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Text ValueStandard Units
11.92IC50=11920nM
42.03IC50=42030nM
4.68IC50=4680nM
9.21IC50=9210nM
7.11IC50=7110nM
3.14IC50=3140nM
13.8IC50=13800nM
4.77IC50=4770nM
5.63IC50=5630nM
9.21IC50=9210nM
IC50Not Determined
6.36IC50=6360nM
2.59IC50=2590nM
7.09IC50=7090nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Replicase polyprotein 1ab
External ID: CHEMBL4495582
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4523582
ChEMBL Target Name: Replicase polyprotein 1ab
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=13.77%
Inhibition=2.35%
Inhibition=21.17%
Inhibition=18.36%
Inhibition=5.381%
Inhibition=18.17%
Inhibition=10.15%
Inhibition=29.56%
Inhibition=18.27%
Inhibition=11.42%
Inhibition=15.4%
Inhibition=7.437%
Inhibition=-3.216%
Inhibition=18%
Inhibition=1.021%
Inhibition=16.4%
Inhibition=2.544%
Inhibition=19.11%
Inhibition=26.15%
Inhibition=5.133%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303810
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueActivity Comment
Hit score=0.07667
Hit score=0.08432
Hit score=0.03233
Hit score=0.1032N=2 (0.182401631,0.023899107)
Hit score=0.0587
Hit score=0.04532
Hit score=0.1213
Hit score=0.1255
Hit score=0.1871
Hit score=0.2217
Hit score=0.1243
Hit score=0.1603
Hit score=0.2724
Hit score=0.3773
Hit score=0.1041
Hit score=0.2216
Hit score=0.6828
Hit score=0.3285
Hit score=0.1291
Hit score=0.1698
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A7681
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Compounds dissolved in DMSO, and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073560 uMActivity at 0.0000367800 uMActivity at 0.0000735600 uMActivity at 0.0001677464 uMActivity at 0.0003678000 uMActivity at 0.0007363003 uMActivity at 0.00153 uMActivity at 0.00368 uMActivity at 0.00723 uMActivity at 0.00914 uMActivity at 0.018 uMActivity at 0.039 uMActivity at 0.092 uMActivity at 0.191 uMActivity at 0.460 uMActivity at 0.910 uMActivity at 1.182 uMActivity at 2.302 uMActivity at 4.834 uMActivity at 11.49 uMActivity at 23.94 uMActivity at 57.45 uMActivity at 115.4 uMActivity at 193.5 uMActivity at 288.3 uMCompound QC
Inhibitor1.0964121.524587Complete curve; high efficacy-5.960.60.996-99.00122.5235-1.10 0 0 0 0 0 0 0-91.416421.20118.089711.55633.2362-23.6097-54.3722-70.1237-91.4164QC'd by GVK
Inactive00041.30296.4095.7452-8.127411.434512.7995.91137.13891.3029QC'd by Vitas
Inhibitor0.05596.749490Complete curve; high efficacy-7.260.60.9836-74.157422.592-1.10 0 0 0 0 0 0 0-78.849512.345912.9899-11.4013-37.5586-53.042-61.5426-65.313-78.8495QC'd by Bosche
Inactive0004-9.339-4.094-2.86744.5071-4.4459-5.3433-2.46713.5091-9.339QC'd by BIOMOL
Inactive0-6.614.95490.77852.5-6.094140 0 0 0 0 0 0 1-8.7946-5.07-2.6335-5.97-10.49513.49112.05881.9174-8.7946QC'd by SIGMA
Inhibitor34.671339.82710Single point of activity-4.462.30310.825-41.327-1.5-30 0 0 0 0 0 0 0-31.93923.6009-5.26172.22954.1407-8.6455-6.9529-4.2362-31.9392QC'd by Microsource
Inactive040 0 0 0 0 0 0 0-13.898620.649216.42211.68939.501116.6467-2.6177-2.1673-13.8986QC'd by Vitas
Inhibitor15.487178.566741Partial curve; partial efficacy-4.810.80.995-76.6721.8947-2.20 0 0 0 0 0 0 0-58.08492.73420.67454.0214-0.609-3.975-12.9528-31.6593-58.0849QC'd by Sequoia
Inactive000426.644512.4429-0.644219.37847.33520.35134.22857.434426.6445QC'd by Microsource
Inactive0-5.92134.95490.79423.5-5.645240 0 0 0 0 0 1-9.4213-2.1113-8.4544-4.6822-8.22654.16062.7472-9.4213QC'd by Tocris
Inactive0004-2.8012-11.1342-2.1920-10.8176-0.6934-3.3166-1.4979-2.8012QC'd by SIGMA
Inactive0-5.764.95490.510428.8996-2.44840 1 0 0 0 0 0 1-2.30523.7377-36.8683-4.4543-19.5675-9.380122.243229.0984-2.305QC'd by Vitas
Inhibitor12.301887.401142Partial curve; high efficacy-4.910.60.9549-73.550113.8509-2.10 0 0 0 0 0 0 0-54.873522.14538.368412.13289.0141-1.3852-8.6537-22.9862-54.8735QC'd by Microsource
Inhibitor27.540450.239310Single point of activity-4.561.75290.9401-50.16480.0744-30 0 0 0 0 0 0 0-39.142.8036-3.03351.3596-6.01625.1159-1.7887-9.2175-39.14QC'd by Microsource
Inactive0-5.310.60.8041-16.01361740 0 0 0 0 0 0 0-11.67817.682513.435821.75976.519717.4375-0.6278-0.9036-11.678QC'd by Enzo
Inhibitor15.487177.547110Partial curve; partial efficacy; poor fit-4.811.1110.829-67.10610.4411-2.40 0 0 0 0 0 0 0-53.05410.743524.16552.70531.738225.7669-4.8999-19.2859-53.0541QC'd by Bosche
Inactive0-6.361.46410.8922-22.47584.540 0 0 0 0 0 0 0-25.49972.54256.30397.767-1.9911-6.3102-26.2299-15.2464-25.4997QC'd by Microsource
Inactive0-4.511.96730.4991426.540 0 0 0 0 0 0 016.846225.531732.670220.285228.569325.635926.981725.029716.8462QC'd by GVK
Inhibitor0.870947.278824Complete curve; partial efficacy-6.064.95490.9676-45.67661.6021-1.20 0 0 0 0 0 0 1-20.51278.27430.9756-1.5573-1.30970.8922-49.683-41.1152-20.5127QC'd by Enzo
Inactive0-6.064.95490.4399-0.676240 0 0 0 0 0 0 1-0.0131.95381.5464-4.31350.312-2.768216.93540.8252-0.013QC'd by Sequoia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303811
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueActivity Comment
Hit score=0.1024N=2 (0.212635467,-0.00776702)
Hit score=0.07542N=2 (0.165375543,-0.014530533)
Hit score=0.6704N=2 (0.78005796,0.560746873)
Hit score=0.1843N=2 (0.272786686,0.095822155)
Hit score=0.1477N=2 (0.173118474,0.122224875)
Hit score=0.4403N=2 (0.614361465,0.266220385)
Hit score=0.1704N=2 (0.179990393,0.160902875)
Hit score=0.06165N=2 (0.143457872,-0.020165946)
Hit score=0.3174N=2 (0.388736093,0.24611012)
Hit score=0.2113N=2 (0.232714858,0.189898759)
Hit score=0.1243N=2 (0.227617003,0.020958197)
Hit score=0.1073N=2 (0.168747786,0.045882357)
Hit score=0.1962N=2 (0.231891094,0.160471653)
Hit score=0.1283N=2 (0.146871317,0.109795157)
Hit score=0.1047N=2 (0.211248858,-0.001805985)
Hit score=0.5553N=2 (0.742183898,0.368346617)
Hit score=0.2137N=2 (0.344299282,0.083050627)
Hit score=0.2294N=2 (0.349402954,0.109452086)
Hit score=0.1922N=2 (0.254418968,0.130061298)
Hit score=0.153N=2 (0.236316448,0.069591595)
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ADRB2293
Protocol: Tox21 Assay Protocol Summary:

CHO-ADRB2 cells were dispensed at 1,000/well in 4uL assay medium into white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Multidrop Combi dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated at 37C and 5% CO2 for an overnight (18-20hr). Then positive control and test compounds dissolved in DMSO were transferred to the assay plates at 23nL using a Pintool station (Wako, San Diego, CA). Following the compound and positive control transfer, 1uL stimulation mix containing 100uM IBMX and 25uM Ro-20-1724 was added to each well of the assay plates using BioRAPTR Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). The assay plates were incubated at room temperature for 0.5hr. Then 2.5ul each d2-labled cAMP and anti-cAMP-cryptate solutions were added separately to each well of the assay plates using an FRD and the assay plates were incubated at room temperature for 1hr. The fluorescence signal was measured at two different wavelengths (665nm and 615nm) using an Envision plate reader (Perkin Elmer, Shelton, CT). Data were expressed as the ratio of 665 nm/615 nm.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000138057 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296300 uM-Replicate_1W530-Activity at 0.0003003888 uM-Replicate_1W530-Activity at 0.0006194162 uM-Replicate_1W530-Activity at 0.00172 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.386 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inconclusive10004-1.9035-1.1923-2.0332-1.0619-12.6616-0.78820.0664-11.7887-6.4513-11.6244-1.9076-2.0225-3.2172-1.90350Single point of activity-5.61024.95490.9089-45.54365-30 0 0 0 0 0 0 0 0 0 0 1 1 1 126.2694
Inactive10004-1.20222.7609-0.01530.9955-0.41571.63592.32520.5928-0.99092.84790.1279-0.03861.8432-1.202210004-31.8285
Inhibitor0.994556.503510004-2.90612.33111.736-3.60126.00595.10040.6447-1.71252.76160.832-1.74680.48220.191-2.90610Single point of activity-6.00242.25260.6374-44.503512-31 0 0 0 0 0 0 0 0 0 1 1 1 1 18.1326
Inconclusive10004-1.3710.9506-2.91191.52635.1535.55271.52731.54971.7024.269902.5531-6.3366-1.37110004-25.7768
Inactive10004-4.2769-0.95591.72782.6067.9793-4.5417-5.96084.89575.48863.60130.2343-3.1649-0.1676-4.276910004-8.7462
Inhibitor8.758121.9554100041.30884.730914.16229.43255.624-1.95912.73144.32472.41837.8238-5.8845-5.16396.60721.30880Single point of activity-5.05761.10.6955-89.934132.0212-30 0 0 0 0 0 0 0 1 0 0 0 0 1 1-23.4699
Inconclusive0.002425.78310Complete curve; partial efficacy; poor fit-8.61330.80.8235-3.7909-29.57391.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.4664-19.6302-7.473-8.9859-9.0898-8.3146-0.2424-6.5275-6.0557-3.3866-1.82-2.8939-4.0012-2.466410004-30.4385
Inactive10004-7.3264-1.5887-10.9052-0.9831-6.53-5.410.9435-5.6079-0.699-2.0867-3.2569-4.2536-2.16180.5621-7.326410-7.92771.80790.6047-24.965740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-31.1667
Inconclusive10004-0.76813.03751.73091.12096.2561-0.0974-8.24190.864-0.54561.50994.4639-1.16054.7076-0.76810Single point of activity-4.95763.1320.706-69.1601-0.5-30 0 0 0 0 0 1 0 0 0 1 1 0 1 1-35.5326
Inconclusive10-5.8521.69240.3729-0.5701440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.18373.34480.978.50642.5766.04151.76024.88511.9267-0.2988-0.0183-1.0279-1.3405-0.183710-8.8024.95490.41826-43.08340 0 0 1 0 0 0 0 0 0 0 0 0 0 022.5365
Inconclusive10-9.12574.44950.3776-1-17.747540 0 0 0 0 0 0 0 0 0 0 0 0 0 02.0705-13.4218-2.2278-1.534-1.45313.8095-2.4909-1.0374-13.5396-0.16050.0263-0.09952.04422.0705100046.6627
Inconclusive10Partial curve; partial efficacy; poor fit-4.15594.95490.9512-25.9952-1-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.246-1.2286-0.8428-1.2278-0.5805-1.8719-0.06640.8961-0.8452-1.9038-2.1419-3.3814-0.974-21.24610-5.25594.95490.5517-28.362-240 0 0 0 0 0 0 0 0 1 1 0 0 0 1-3.0491
Inconclusive10004-2.6403-1.5203-3.2668-0.3318-5.31293.2585-4.0841-4.30851.19516.0144-4.8227-2.25281.5709-2.64030Partial curve; high efficacy; poor fit-5.16334.95490.4313-80.8838-1.5-2.30 0 0 0 0 0 0 0 0 0 0 0 1 1 1-1.3949
Inactive10004-0.26721.230113.62434.24763.99616.594517.55362.17369.11160.1969-3.48061.5252-2.0777-0.267210-5.31244.95490.3735-19.39133.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.3739
Inactive10004-5.77735.11124.0288-1.9434-1.021412.92192.34717.4846-2.0121.291-2.74985.90195.369-5.777310004-4.4961
Inconclusive10004-15.4564-4.51941.21191.7588-11.93060.5255-1.2623.2933-2.6412-3.3809-1.071-2.7851-1.8097-15.456410-4.66420.70.437326.1319-6.859441 0 0 0 1 0 0 0 0 0 0 0 0 0 10.7866
Inactive100045.20961.56415.30634.99462.482-1.21514.35076.00556.2785-0.47860.86696.1344.32315.209610004-35.4391
Inactive100042.47121.4625-2.9807-1.69247.24483.0542-12.2145-8.3996-2.4864.052-1.4266-1.5593-0.16762.4712100043.4572
Inactive10-4.91021.46410.523614.5-0.475640 0 0 0 0 0 0 0 0 0 0 0 0 0 013.887.5564-7.4796-3.3029-4.4182-3.7928-2.6927-0.11982.6654-1.01760.301216.57859.432213.88100043.7428
Inactive100040.5160.0357.1699-4.87981.4861-5.9734-8.5349-6.6743-1.7256-1.1817-1.1379-5.50792.8730.51610004-5.7554
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ADRB2713
Protocol: Tox21 Assay Protocol Summary:

CHO-ADRB2 cells were dispensed at 1,000/well in 4uL assay medium into white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Multidrop Combi dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated at 37C and 5% CO2 for an overnight (18-20hr). Then positive control and test compounds dissolved in DMSO were transferred to the assay plates at 23nL using a Pintool station (Wako, San Diego, CA). Following the compound and positive control transfer, 1uL agonist-stimulation mix containing 1nM Isoproterenol HCl, 100uM IBMX and 25uM Ro-20-1724 was added to each well of the assay plates using BioRAPTR Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). The assay plates were incubated at room temperature for 0.5hr. Then 2.5ul each d2-labled cAMP and anti-cAMP-cryptate solutions were added separately to each well of the assay plates using an FRD and the assay plates were incubated at room temperature for 1hr. The fluorescence signal was measured at two different wavelengths (665nm and 615nm) using an Envision plate reader (Perkin Elmer, Shelton, CT). Data were expressed as the ratio of 665 nm/615 nm.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000137707 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296300 uM-Replicate_1W530-Activity at 0.0003002588 uM-Replicate_1W530-Activity at 0.0006197232 uM-Replicate_1W530-Activity at 0.00170 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.386 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inhibitor26.603267.916510004-6.3959-9.65890.68632.7866-13.8272-6.7622-5.1896-0.7481-5.27594.03470.82940.1619-7.9826-6.39590Partial curve; partial efficacy-4.57512.04790.7981-71.9165-4-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-55.9973
Inactive10-4.62514.44950.3528-7.16493.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.38749.90032.8880.83753.8232-0.0972-3.85071.63986.05136.86712.68588.8472-0.8502-6.3874100041.575
Inactive10-6.97511.47810.3563-3.5961240 0 0 0 0 0 0 0 0 0 0 0 0 0 10.93160.12450.04624.37542.76350.5086-0.9132-2.76892.6163-8.8301-3.1415-5.9818-0.09820.9316100041.7546
Inactive10004-0.2652-5.20890.1059-0.2104-5.15230.33386.5915-0.1964-2.77990.7841-0.7171-11.48410.0954-0.265210004-13.1319
Inactive100042.5869-2.9649-3.11563.2094-2.83759.1891-4.0873-2.306-3.35572.25610.25920.4568-2.76022.586910004-1.7942
Inactive10-8.42514.95490.42-1.5675840 0 0 0 0 0 0 0 0 0 0 0 0 0 13.10992.05513.45141.5277-1.18820.19451.17012.6784-0.2053-6.4479-0.458-3.6987-4.65953.109910-6.57510.50.3897-7.94783.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.9647
Inactive100041.98244.9364-3.0777-2.52245.8788-4.393-2.1514-6.5660.2639-2.3165-0.97250.1618.67231.9824100046.8262
Inactive100043.1910.64224.5969-8.3735-6.2557-10.06561.9483-0.0245-0.5998-6.34343.4655-0.97126.44013.19110-6.42514.95490.47171-6.555840 0 0 0 0 0 0 0 0 0 0 0 0 0 01.4044
Inactive100043.06910.94732.7335-0.3539-2.50762.6313-2.14111.34421.3076-1.59431.5055-0.4395-0.98173.0691100041.074
Inactive100040.03460.7513-5.05642.3416-3.78150.6279-8.57720.96422.5971-5.43511.94880.0125-4.35290.0346100041.8201
Inactive100040.6895-3.70214.9864-1.54015.41435.0376-4.7424-5.3192-0.37944.4337-3.11858.58982.10140.6895100040.0062
Inactive100041.35410.6932-6.5104-4.10014.12961.40140.1852-2.5615-2.9103-6.16262.11950.64771.75491.354110004-0.079
Inactive10004-0.9612-2.32050.75015.3012-0.3654-0.41856.8872-1.988210.93541.3283-3.35076.4187-0.5006-0.961210-8.87513.06540.39511.5-6.166340 0 0 0 0 0 0 0 0 0 0 0 0 0 05.4117
Inactive10-4.97510.70.3315-10.872-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.76180.98150.1-0.85683.8492-10.310.16961.4622-0.195-5.3525-2.1777-5.7002-7.2375-7.761810-7.52514.95490.3969-2.9301540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.0376
Inactive10-5.12514.95490.8156-9.2611-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.12810.0145-0.6779-1.47220.3898-1.23510.5729-4.44590.86280.7235-0.3998-7.3742-9.8009-8.128110004-2.0593
Inactive100046.04370.32725.2199-1.386516.5133-4.78731.16280.41731.29560.90511.13123.78936.19046.0437100040.8526
Inactive10004-5.2833-3.6332-8.5443-7.987-8.28162.6995-7.1202-2.40580.91532.5108-1.3669-7.4886-7.4328-5.2833100046.8517
Inhibitor29.8493106.094510-5.47512.84730.42146.5-2.542840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.2442-0.53315.2895-5.86780.6544-0.4618-5.09910.1718-8.184-9.20241.59976.35576.1854-3.24420Partial curve; high efficacy-4.52512.12110.9077-108.0945-2-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.8897
Inactive10-6.02514.95490.40980-4.031340 0 0 0 0 0 0 0 0 0 0 0 0 0 02.6436-7.1138-4.8994-1.2953-3.42690.0695-5.181-8.7761-5.8014-2.75760.2413-0.1351-2.45232.643610004-7.8883
Inactive10004-5.3863-7.35993.98542.9754-2.40971.18239.4234-0.41260.864-0.3003-2.479-0.03810.1317-5.386310004-9.0143
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: DRD2945
Protocol: Tox21 Assay Protocol Summary:

DRD2-Hek293 cells were dispensed at 600 cells/3uL/well in 1536-well white plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 24 h, 1 uL of Ro20-1724 at final concentration of 0.1 mM was transferred to the assay plate by a Flying Reagent Dispenser. Following Ro20-1724 addition, 23 nL of compound dissolved in DMSO, positive controls or DMSO only was added to the assay plates via Wako pintool station. The assay plates were incubated at room temperature for 10 min. Next, 1 uL of mixture of NKH477 (final concentration at 200 nM) and quinpirole (final concentration at 12 nM) was added into the plates. After the assay plates were incubated at room temperature for an additional 30 min, 2.5 ul/well of cAMP-d2 and 2.5 ul/well of anti-cAMP-cryptate were added respectively into the assay plates using a Flying Reagent Dispenser. The plates were incubated at room temperature for 1 h. The fluorescence intensity in the plates was measured at 340 nm excitation and 665 & 620 nm emission by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060292 uM-Replicate_1W530-Activity at 0.0000139277 uM-Replicate_1W530-Activity at 0.0000552087 uM-Replicate_1W530-Activity at 0.0001297661 uM-Replicate_1W530-Activity at 0.0003003480 uM-Replicate_1W530-Activity at 0.0006206701 uM-Replicate_1W530-Activity at 0.00170 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.348 uM-Replicate_1W530-Activity at 1.074 uM-Replicate_1W530-Activity at 3.280 uM-Replicate_1W530-Activity at 8.379 uM-Replicate_1W530-Activity at 18.94 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 242.9 uM-Replicate_1W530-Activity at 865.8 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive100043.78813.72091.98610.20610.59235.59482.53080.60822.30311.88620.3033-2.23441.87823.788110004-12.0188
Inactive100040.30120.52940.6626-2.6038-0.5572-0.6631-4.33661.0325-2.759-0.3338-0.3287-1.63422.49720.3012100042.5444
Inactive10004-6.3367-0.20894.28190.94444.1311-1.1259-2.3025-0.8518-3.0168-0.69982.3696-1.04735.4453-6.336710-4.87513.51170.6776-24.2714-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 12.914
Inactive10004-1.1765-2.02963.5024-1.9703-0.15791.9613-0.75732.76970.8721.72771.1044-0.05681.933-1.176510-6.12514.95490.4361-5.3789240 0 0 0 0 0 0 0 0 0 0 0 0 0 116.187
Inactive10-4.44014.95490.7066-19.0899240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.90474.8233-2.51545.04834.70586.1601-0.2063-0.8092-0.6546-4.17011.85590.3717-17.5749-0.904710-4.49014.95490.471515.5-4.348640 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.0917
Inconclusive10-6.62354.95490.7986-0.6511040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.63988.774811.18327.61489.427810.847712.24230.7218-1.8373-2.18071.01625.3861-1.696-3.639810004-1.5758
Inactive100041.33252.41660.0324-1.17531.0360.22312.63193.94840.94140.00221.27583.2279-2.80021.332510004-3.3592
Inactive10-6.37992.72020.319-1.29553.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.3155.53032.4743-0.4098-0.05774.777410.7719-2.01031.7767-1.0637-1.2042.5912-3.5795-3.31510-6.32994.95490.42623.5-6.413140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.295
Inactive100041.11512.34553.30752.55170.31210.86413.3572-5.8070.82230.74510.4398-3.3457-5.97791.115110-7.08462.04790.54874-12.505140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-9.5005
Inactive100041.63771.2371-1.25830.3296-1.6140.7175-1.114-0.0071-2.3580.54470.1386-1.0325-0.62621.637710004-2.264
Inactive100041.1729-5.37470.0618-1.16140.2075-0.5657-2.68830.98772.79770.48074.20440.5734-4.58271.172910-7.72874.95490.3377-4.06432.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.4636
Inhibitor50.887851.364110004-0.0970.4130.80160.55140.49890.17153.02080.70020.7634-4.9454-3.23730.4082-4.1558-0.0970Partial curve; partial efficacy-4.29343.06540.7755-53.8641-2.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-47.2455
Inactive100047.09728.61190.86441.2866-1.15580.06177.65980.00716.608-1.8979-2.1702-0.918410.71347.097210-4.66014.44950.5285-18.6347-340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.5019
Inactive100040.4698-1.0082-3.0359-1.3764-2.8847-2.1219-1.72584.0502-6.0703-2.72140.76450.6902-0.23090.469810004-4.9773
Inactive100045.8424.59930.09510.5509-0.07364.4281-2.8904-1.95170.0719-0.5266-2.90590.46610.03965.84210-4.15331.210.5077-31.931240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.2758
Inconclusive100042.20030.65450.18076.1358-0.38062.10074.9512-0.01961.9422-1.56120.41822.5985-2.1292.200310-6.56052.72020.4244-1.5-9.440940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-12.2578
Inhibitor31.4373115.3525100049.71694.21783.58235.13815.09542.57424.22143.54180.04322.4418-1.71227.3565-0.25439.71690Partial curve; high efficacy-4.50261.24750.9516-117.8525-2.5-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-103.3794
Inactive100041.7529-5.7942-2.1210.23431.62890.87140.2124-5.88470.01861.5276-1.9768-1.2986-3.43591.752910-8.09594.95490.48860.5917840 0 0 0 0 0 0 0 0 0 0 0 0 0 00.6765
Inactive100043.39870.6520.80240.3115-3.13092.1040.4118-2.7174-3.73120.0892-0.14594.0124-0.74333.398710-8.74514.95490.45570.928714.540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.1127
Inactive100045.282.1409-0.18040.24510.4128-3.92832.74470.34230.07910.359-0.25380.8178-2.33135.2810004-1.3082
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: DRD2180
Protocol: Tox21 Assay Protocol Summary:

DRD2-Hek293 cells were dispensed at 600 cells/3uL/well in 1536-well white plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 24 h, 1 uL of Ro20-1724 at final concentration of 0.1 mM was transferred to the assay plate by a Flying Reagent Dispenser. Following Ro20-1724 addition, 23 nL of compound dissolved in DMSO, positive controls or DMSO only was added to the assay plates via Wako pintool station. The assay plates were incubated at room temperature for 10 min. Next, 1 uL of NKH477 at 200nM was added into the plates. After the assay plates were incubated at room temperature for an additional 30 min, 2.5 ul/well of cAMP-d2 and 2.5 ul/well of anti-cAMP-cryptate were added respectively into the assay plates using a Flying Reagent Dispenser. The plates were incubated at room temperature for 1 h. The fluorescence intensity in the plates was measured at 340 nm excitation and 665 & 620 nm emission by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000137707 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296300 uM-Replicate_1W530-Activity at 0.0003002588 uM-Replicate_1W530-Activity at 0.0006189798 uM-Replicate_1W530-Activity at 0.00171 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.386 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10-9.17434.95490.4482-3.18846.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.07816.0843-0.8272-3.4248-7.0165-0.7165-1.5939-6.0807-6.8337-3.16772.3771-1.0033-5.7858-1.5510004-2.7583
Inactive10-4.56371.86170.317890.084640 0 0 0 0 0 0 0 0 0 0 0 0 0 10.0842-0.0855-0.2953-0.78052.34661.2131-0.54523.1167-3.3842-0.91893.75641.40566.4780.084210004-4.2236
Inactive100042.61982.3466-0.37735.5914.99152.11680.87533.1726-0.17420.9304-1.192-0.56531.70682.619810004-6.2418
Inactive100046.3560.92680.5680.6444-3.3685.672.3853-0.05552.7361-3.48357.347-3.04965.74596.356100043.4789
Inactive100041.38231.31710.97261.5261-8.2713-38.61011.4699-0.6371-5.1128-8.1546-1.1688-0.5786-0.66451.3823100048.8154
Inactive10004-2.5144-2.361-1.80391.85040.1129-6.2676-1.336-3.9127-3.9292-2.7130.026-2.79-2.1424-2.514410004-9.9999
Inactive100048.63938.07697.9985-2.61410.32086.27480.56646.16683.97512.40730.27918.65336.08258.6393100040.6824
Inactive10004-4.5511-0.5715-12.6079-5.3348-1.7778-1.64430.7428-13.8301-1.3699-2.6117-9.8602-7.4651-3.7149-4.5511100044.8975
Inactive10004-8.9924-2.5393-12.2689-12.3285-8.4096-5.3726-7.3661-8.2488-6.5273-10.2917-10.0818-0.9401-19.8028-8.992410-4.56374.95490.6441100.364840 0 0 0 0 0 0 0 0 0 0 0 0 0 08.3824
Inactive100040.5065-4.7724-1.7416-5.05921.11050.443-0.1512-1.416-1.4307-0.5117-7.58251.11541.19672.93930.5065100042.402
Inactive100040.07942.87210.18864.94540.2886-2.1392-1.7328-1.01662.15434.9444.9611.73843.84360.079410-5.06374.95490.4347-3.07543.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.2874
Inactive10-4.61644.0950.4209-7.778140 0 0 0 0 0 0 0 0 0 0 0 0 0 12.11662.02-0.42232.25972.48460.06621.20842.5829-1.68581.7929-0.6289-1.1-6.89832.116610-4.11644.95490.5915-20.3885-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.3238
Inactive10004-7.0632-0.8623-1.7916-4.2652-5.9669-19.4504-1.91220.824-2.2999-5.5153-0.4675-5.37812.0763-7.063210-8.81374.95490.73241-15.784740 0 0 0 0 0 0 0 0 0 0 0 0 0 03.2717
Inactive100045.45724.7104-1.6933-3.19594.97480.59361.7222-0.1931.27552.5585-4.68520.39195.48635.457210-9.04334.95490.6699-0.51411.540 0 0 0 0 0 0 0 0 0 0 0 0 0 01.4299
Inactive10004-5.15337.6944-0.2819-6.74360.13834.2317-8.8165.28882.3311.64635.25816.3561-1.5635-5.153310-8.71374.44950.67941.5-14.151240 0 0 0 0 0 0 0 0 0 0 0 0 0 01.5537
Inactive100047.48515.0097.9161-5.82395.4781-0.20210.73765.95164.1964-6.02863.1953-2.5872.51947.4851100042.0117
Inactive100047.63123.15953.60054.23419.422-0.7563.62193.93153.42863.89981.27179.0227-0.49517.631210004-6.9865
Inactive10-5.36374.95490.3650.132640 0 0 0 0 0 0 0 0 0 0 0 0 0 111.41172.26859.495711.56072.32788.75936.01856.48955.66755.3341-2.80674.5233-1.542111.411710004-1.6128
Inactive100042.8507-1.44118.21990.12610.2712-2.1386-1.41324.99742.20190.50950.32360.58160.98078.83382.8507100040.3148
Inactive10004-3.5331.7914-3.9103-4.2814-4.8026-0.23944.0174-2.4595-1.52260.851.611-2.87492.3635-3.53310004-4.1257
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CHRM1834
Protocol: Assay Protocol Summary:

CHRM1-CHO cells were dispensed at 1000 cells/3uL/well in 1536-well black-clear bottom plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 h, 3 uL of Dye Loading Buffer was transferred to the assay plate by a Flying Reagent Dispenser. The assay plates were incubated at 37 C for 1h. For agonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 2 min at 1 sec intervals. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 3 min at 1 sec intervals. Each test compound was measured at 15 concentrations in three independent runs.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152025 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00040.27-0.01710.2452-0.00120.080.07230.2279-0.64050.02840.0796-0.0665-0.0639-0.02560.27QC'd by SigmaAldrichInactive0
Inactive00040.3979-0.06510.78140.003-0.08590.1712-0.03250.09370.0666-0.442-0.6501-0.7181-1.19180.3979QC'd by Toronto ResearchInactive0
Inactive00040.50960.13750.02540.15070.01870.023-0.0882-0.04940.26750.23570.15260.0353-0.51360.5096QC'd by SigmaAldrichInactive0
Inactive00042.53080.77180.56770.1541-0.18960.0586-0.0992-0.19140.07380.69750.14260.09660.34082.5308QC'd by SIGMAInactive0
Inactive0004-1.14720.10470.25460.15670.13560.05240.35320.1530.0574-0.6714-0.19020.1471-1.2293-1.1472QC'd by SIGMAInactive0
Inactive00040.14630.0224-0.33040.05520.09030.0693-0.08240.1615-0.03260.09990.3798-0.07420.35760.1463QC'd by SIGMAInactive0
Inactive0004-0.0699-0.94060.80630.77990.03390.7610.03490.21810.49060.0890.2004-0.0501-0.0028-0.0699QC'd by SIGMAInactive0
Inactive00041.83420.1116-0.00320.11720.23360.2218-0.15310.0723-0.0177-0.04750.0390.36720.25951.8342QC'd by SigmaAldrichInactive0
Inactive00041.2961-0.0487-0.113-0.27430.0322-0.18530.2616-0.01810.4137-0.05260.35890.45560.61241.2961QC'd by SigmaAldrichInactive0
Inactive0004-0.17021.55020.53860.099-0.1571-0.2841-0.4676-0.23710.2585-0.29890.42120.2244-0.329-0.1702QC'd by SIGMAInactive0-4.24844.95490.9849
Inactive00040.617-0.0348-0.0116-0.15060.12690.09220.04280.13080.67190.54110.05040.04340.07380.617QC'd by SigmaAldrichInactive0
Inactive00040.08250.10830.13780.04780.2340.03580.0664-0.12370.0503-0.01640.11520.24270.00820.0825QC'd by SIGMAInactive0
Inactive00040.29450.04740.51170.20190.25530.09380.3703-0.06840.1512-0.01270.2949-0.07560.07070.2945QC'd by SigmaAldrichInactive0
Inactive0004-0.47420.19480.86240.64810.36120.4680.4992-0.19240.7415-0.0520.3014-0.4759-0.7733-0.4742QC'd by SIGMAActivator4.888238.3142Complete curve; partial efficacy-5.31084.95490.9876
Inactive0004-0.10730.05280.15780.0556-0.06520.094-0.0707-0.09840.15540.01480.06-0.683-0.0854-0.1073QC'd by SIGMAInactive0
Inactive0004-0.38280.7081.10930.27520.50230.35130.5920.2070.31280.31150.00490.15090.0186-0.3828QC'd by SIGMAInactive0
Inactive00043.19140.05370.0627-0.0199-0.91560.34450.1644-0.0051-0.06990.12160.44840.16630.14663.1914QC'd by Spectrum ChemicalInactive0
Inactive0-8.86033.990.97980.24231740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.08198.09170.91440.3470.2061.69190.27670.2627-0.1985-0.0993-0.2147-0.0596-0.0858-0.0819QC'd by SIGMAInactive0
Inactive00040.11330.20950.15290.2804-0.00250.29590.57160.22840.33210.03070.11970.07720.34590.1133QC'd by SigmaAldrichInactive0
Inactive00040.53410.02420.21240.18710.04730.10960.04040.0920.12340.01120.1629-0.07080.20290.5341QC'd by SigmaAldrichInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CHRM1997
Protocol: Tox21 Assay Protocol Summary:

CHRM1-CHO cells were dispensed at 1000 cells/3uL/well in 1536-well black-clear bottom plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 h, 3 uL of Dye Loading Buffer was transferred to the assay plate by a Flying Reagent Dispenser. The assay plates were incubated at 37 C for 1h. For antagonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. After 5 min incubation at room temperature, 1.5 uL of acetylcholine at 50nM was added to each well. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 3 min at 1 sec intervals. Each test compound was measured at 15 concentrations in three independent runs.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000039960 uM-Replicate_1Activity at 0.0000091663 uM-Replicate_1Activity at 0.0000362847 uM-Replicate_1Activity at 0.0000862850 uM-Replicate_1Activity at 0.0001998674 uM-Replicate_1Activity at 0.0004124603 uM-Replicate_1Activity at 0.00113 uM-Replicate_1Activity at 0.00347 uM-Replicate_1Activity at 0.00893 uM-Replicate_1Activity at 0.020 uM-Replicate_1Activity at 0.045 uM-Replicate_1Activity at 0.102 uM-Replicate_1Activity at 0.232 uM-Replicate_1Activity at 0.710 uM-Replicate_1Activity at 2.174 uM-Replicate_1Activity at 5.582 uM-Replicate_1Activity at 12.62 uM-Replicate_1Activity at 28.26 uM-Replicate_1Activity at 61.51 uM-Replicate_1Activity at 159.9 uM-Replicate_1Activity at 580.7 uM-Replicate_1Activity at 1231.0 uM-Replicate_1Activity at 2752.0 uM-Replicate_1Activity at 6155.0 uM-Replicate_1Activity at 13760.0 uM-Replicate_1Activity at 30770.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.1781-14.6077-15.74035.874-6.19418.893-5.649710.7344-0.67673.7136-6.5739-2.1499-21.2783-2.1781QC'd by SIGMAInactive0
Inactive0-6.1260.30.4906-11.7304-33.739340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.5369-31.6558-25.1796-28.7381-31.0798-26.2723-27.0785-30.5027-26.1541-8.1086-12.2914-19.9415-24.8788-16.5369QC'd by SIGMAInactive0
Inactive000415.11824.3534-3.1877-2.3826-5.7413-2.494211.75430.97083.76215.91024.486711.0592-5.946515.1182QC'd by SIGMAInactive0
Inactive0-8.52620.80.37567.5-8.95740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.0338-3.64071.60920.62293.187712.91231.74593.92468.020910.518311.639515.6309-5.7975-7.0338QC'd by SIGMAInactive0
Inactive0-6.0263.990.37841.5-16.326140 0 0 0 0 0 0 0 0 0 0 0 0 0 07.701-23.9593-2.61690.34194.1756-23.8273-28.1884-27.1927-13.1416-3.4634-3.930911.7786-7.39137.701QC'd by SIGMAInactive0-7.4761.3310.4129
Inactive0-8.87624.95490.4467-2.89869.540 0 0 0 0 0 0 0 0 0 0 0 0 0 11.2264.0632-6.2638-6.4961-4.2253-3.5816-3.9002-1.843-3.68491.19333.89413.4558-6.99891.226QC'd by SIGMAInactive0
Inactive000417.853-4.4191-4.34458.438221.648-5.45146.6976-11.093111.255112.5287-7.84059.850416.079317.853QC'd by SIGMAInactive0
Inhibitor14.929466.177610Single point of activity-4.8264.44950.89-59.67766.5-30 0 0 0 0 0 0 0 0 0 0 0 0 0 1-15.344512.41639.71031.67098.92985.04529.81652.21698.6338-9.05192.0403-8.8885-59.3874-15.3445QC'd by CrescentInhibitor14.929443.584610Partial curve; partial efficacy; poor fit-4.8261.24750.7244
Inactive0004-12.3393-5.4707-7.76841.2125-0.9372-2.8638-4.8159-2.7306-8.3906-9.8909-5.1158-7.2832-3.7752-12.3393QC'd by CrescentInactive0
Inactive0004-12.39951.73690.337212.25698.1175-3.8979-0.5168-2.9245-1.5012-11.34040.83976.57380.9346-12.3995QC'd by CrescentInactive0
Inactive0-7.4764.95490.44240.4896-18.399340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.4979-11.8174-3.4832-35.6655-28.5631-0.27183.2831-4.3744-4.3198.29879.438-3.47050.9414-4.4979QC'd by SIGMAInactive0
Inactive000411.53510.193311.9123-7.312714.60326.2774-3.41324.3898-1.954310.42329.88493.05612.716611.5351QC'd by SIGMAInactive0
Inhibitor0.594430.146810Partial curve; partial efficacy; poor fit-6.2263.92950.7596-31.1468-1-2.40 0 0 0 0 0 0 0 0 0 1 1 1 1 19.5925-8.13272.24441.75489.3564-5.7864-0.27772.5376-21.72486.41512.81351.15442.42899.5925QC'd by SIGMAInactive0
Inactive0-5.2763.990.4615-5.34586.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.30194.76232.487611.73962.3257-6.645112.017214.48989.03815.5870.4265-6.2237-6.9549-2.3019QC'd by SIGMAInactive0-4.3764.95490.5619
Inactive00042.05448.146913.882312.5534-5.61650.912412.01381.37735.791415.21471.24863.25714.80342.0544QC'd by SIGMAInactive0
Inhibitor8.395486.565182Complete curve; high efficacy-5.0762.25260.9515-80.06516.5-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-75.405-0.47175.053514.06375.580411.760223.03491.4555-1.71019.2627-17.022-54.0908-79.057-75.405QC'd by SIGMAInactive0-4.3764.95490.4538
Inactive00041.3209-3.56471.30272.7209-12.34330.54250.6416-2.4475-9.1264-0.7083-1.51823.5135-1.75421.3209QC'd by SIGMAInactive0
Inactive00040.14032.2597-2.059213.664116.96353.773113.14130.69514.996-1.62290.30745.6118.65320.1403QC'd by SIGMAInactive0
Inactive0-5.58383.990.6268-0.5-10.788840 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.6985-10.3141-12.3897-15.0539-7.0521-6.4389-18.9907-5.2846-10.0691-6.4352-0.26281.1904-1.6416-1.6985QC'd by SIGMAInactive0
Inactive000410.66146.5582-3.2554-3.2146-2.04712.598611.13443.1739-1.526-0.57044.82454.971210.532110.6614QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CRE506
Protocol: Tox21 Assay Protocol Summary:
CRE-bla Hek 293T cells were suspended in assay medium (DMEM containing 10% dialyzed FBS, 0.1 mM NEAA, 1 mM sodium pyruvate and 25 mM HEPES) and dispensed at 2,000 cells/4 uL /well into 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for 18 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool workstation (Kalypsys, San Diego, CA), followed by addition of 1 only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of 1.25uM NKH477 (0.25 uM as final concentration) in assay medium using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA). The plates were incubated at 37 C and 5% CO2 for 3 hrs. Then 1 uL of LiveBLAzer B/G FRET substrate (Invitrogen, Carlsbad, CA) was added to each well using Bioraptr Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). The plates were incubated at room temperature for 2 h.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000137707 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296798 uM-Replicate_1W530-Activity at 0.0003000028 uM-Replicate_1W530-Activity at 0.0006177381 uM-Replicate_1W530-Activity at 0.00171 uM-Replicate_1W530-Activity at 0.00519 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.391 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.44 uM-Replicate_1W530-Activity at 92.40 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-7.0159-0.28761.01321.44170.0888-9.1268-1.0522-7.4421-2.13092.3-0.6113-7.015910004-3.4056
Inactive10004-3.011-1.145-2.4844-1.55333.485-0.204-2.4902-1.54362.3767-6.3498-2.685-3.011100040.7393
Inactive10004-0.47-2.8951-3.2523-3.7349-2.26785.50733.05993.31041.24725.2625-0.1696-0.4710004-1.555
Inactive10004-0.09036.7111-0.5976-0.3144-0.47654.1544-6.4709-0.4438-7.8642.2606-1.579-0.0903100040.228
Inconclusive10004-0.2489-6.5215-0.8591-0.5168-7.3815-0.3741.3251-4.3898-1.81870-5.0418-0.24890Single point of activity-4.94454.95490.8866-44.0901-1.7908-30 0 0 0 0 0 0 0 0 0 1 12.9202
Inactive10004-5.6294-14.3173-2.7201-11.2343-4.43723.4425-5.249628.2483-6.79752.1333-6.1463-5.629410-8.24452.33320.5422-2-14.519340 0 0 0 0 0 0 0 0 0 0 1-7.0593
Inactive10004-4.8656-4.3458-5.475-4.89231.908812.6287-0.6734-6.886-6.7235-12.2506-0.9244-4.865610004-0.1056
Inactive100042.05360.3109-7.7771-4.05191.735913.82374.1529-1.641-6.3339-7.8549-1.84152.053610-8.54450.20.35041.5-15.408240 0 0 0 0 0 0 0 0 0 0 01.5023
Inactive100041.8357-3.8712-4.59684.9056-2.4421-0.4821-0.70024.091-5.05424.7764-0.18731.835710-6.84454.95490.3731-1.2664840 0 0 0 0 0 0 0 0 0 0 0-6.472
Inconclusive10-8.44454.95490.4825-0.97971140 0 0 0 0 0 0 0 0 0 0 0-2.985812.2192-7.4831-2.76110.9594.608-1.19161.5553-4.61891.86440.8695-2.98580Complete curve; partial efficacy; poor fit-8.44454.95490.854-2.188620-1.40 0 0 0 0 0 0 0 0 0 0 0-3.7347
Inactive10-7.69454.95490.30740-6.674740 0 0 0 0 0 0 0 0 0 0 16.9665-0.2746-13.4789-0.7541.4976-6.63441.89750.04562.39343.2814-4.07626.966510004-1.252
Inactive10004-0.47391.766-10.94371.36752.373-9.08121.0872-1.62221.10851.03521.2078-0.473910004-1.5827
Inactive10-4.44452.40640.9192-16.0230.540 0 0 0 0 0 0 0 0 0 0 0-13.76922.63221.58520.43591.6531-1.4042-0.73890.9511-0.33230.0369-10.5155-13.769210-4.19454.95490.57139-3.14940 0 0 0 0 0 0 0 0 0 0 07.2634
Inactive100048.62161.66121.39551.5105-8.28851.1474-1.52842.0426-0.73990.4137-1.85788.621610004-2.0298
Inactive10004-4.4756-0.29490.23863.43141.14790.7678-0.0067-0.6507-5.9741-0.2067-0.9416-4.475610004-3.061
Inactive100045.8601-2.39410.0423-2.0754.7846.2997-0.85951.393-3.01113.55965.32115.860110004-9.2067
Inconclusive10-4.24454.95490.427210.5-2.309340 0 0 0 0 0 0 0 0 0 0 09.5331-2.85560-1.2063-0.52341.9291-1.3959-2.6682-0.0439-13.5911-0.2019.533110-4.19454.95490.4089-3.448340 0 0 0 0 0 0 0 0 0 0 07.6869
Inactive10-4.28664.95490.72825.5-1.172640 0 0 0 0 0 0 0 0 0 0 023.3828-8.06053.02756.3622-3.8991.2563-5.1797-5.777-0.78790.19013.771823.382810-4.18664.95490.6532-22.1907-340 0 0 0 0 0 0 0 0 0 0 0-18.4923
Inconclusive100045.4646-3.9154-3.2006-6.41313.52925.1932-1.12710.5761-20.3247-0.5782-7.18015.464610004-5.264
Activator45.240774.820710-7.89454.95490.36863-7.172940 0 0 0 0 0 0 0 0 0 0 1-4.09-4.1888-10.14418.5838-1.725112.80163.66663.2286-2.06960.7385-1.1706-4.090Partial curve; high efficacy-4.34453.06540.983172.728-2.09272.10 0 0 0 0 0 0 0 0 0 0 064.1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CRE623
Protocol: Tox21 Assay Protocol Summary:
CRE-bla Hek 293T cells were suspended in assay medium (DMEM containing 10% dialyzed FBS, 0.1 mM NEAA, 1 mM sodium pyruvate and 25 mM HEPES) and dispensed at 2,000 cells/5 uL /well into 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for 18 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool workstation (Kalypsys, San Diego, CA). After the plates were incubated at 37 C/5% CO2 for 3 hrs, 1 uL of LiveBLAzer B/G FRET substrate (Invitrogen, Carlsbad, CA) was added to each well using Bioraptr Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). The plates were incubated at room temperature for 2 h.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000137707 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296300 uM-Replicate_1W530-Activity at 0.0003002588 uM-Replicate_1W530-Activity at 0.0006197232 uM-Replicate_1W530-Activity at 0.00170 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.386 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-0.9548-0.4195-0.08090.01770.7848-1.9753-7.8495-0.2201-5.8525-0.1843-6.667-6.1435-0.8948-0.9548100040.4943
Inconclusive33.491535.467210Single point of activity-4.47514.95490.843234-1.467230 0 0 0 0 0 0 0 0 0 0 0 0 0 031.5847-0.2053.1711-0.15032.02621.8413-4.6774-6.6393-0.2496-0.3165-2.4959-5.1038-6.43831.5847100040.7055
Fluorescent21.1317233.52310Partial curve; high efficacy-4.67511.66040.9916233.382-0.14082.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0187.9080.2599-1.6287-1.3781-0.2984-4.561-5.7662-0.1876-0.89793.775318.200944.8649106.298187.90810004-7.3866
Inactive10-9.12514.95490.3604-3.3986940 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.97486.1565-4.2866-4.2034-1.1608-2.7993-8.2488-3.77590.147-6.6878-0.72651.7247-4.6409-3.9748100040.7006
Inactive10004-2.523-0.126-0.55750.26870.577-0.4465-1.82971.4459-0.8687-0.2229-1.2617-1.1583-2.804-2.523100040.1481
Inactive10004-3.3158-2.46060.8744-2.4805-1.96530.2783-2.1155-3.1759-0.73280.0273-2.7411-1.1742-2.5861-3.3158100040.3542
Inactive10004-6.3298-3.0655-0.5983-3.9559-3.2297-0.1472-0.9072-0.8472-0.4548-2.3342-4.8197-0.9701-5.2874-6.3298100040.0515
Inactive10004-1.6718-2.7534-3.0434-3.2368-0.5266-0.94970.8324-0.4991-0.1271-2.3961-5.9765-2.88891.3265-1.671810004-0.8308
Inactive100040.2704-0.01130.2093-0.13591.8534-1.9442-1.318-1.36660.26060.3476-0.5964-4.328-0.650.2704100040.2962
Inactive100046.1074-1.09610.1205-0.9377-0.83138.31174.16744.893111.21568.51340.08540.32950.12876.107410004-1.6275
Inconclusive66.265742.352310Partial curve; partial efficacy; poor fit-4.17872.18760.744138.0307-4.32152.40 0 0 0 0 0 0 0 0 0 0 0 0 0 029.2246-1.7761-13.0089-0.6771-0.1398-0.17050.3188-8.468-7.9781-16.97650.4529-0.721710.880929.224610004-3.7076
Fluorescent28.616390.842810Partial curve; high efficacy-4.54341.10.981890.3256-0.51722.10 0 0 0 0 0 0 0 0 0 0 0 0 0 071.8878-4.4616-0.0053-3.23970.62975.4330.79530.3464.285511.413917.470133.335455.296271.8878100044.8243
Inconclusive34.66854.985810Partial curve; partial efficacy-4.46011.10.947255.96930.98352.20 0 0 0 0 0 0 0 0 0 0 0 0 0 046.8430.3409-1.0852-0.7636-0.33174.23040.81593.05980.71718.24410.756619.145128.547346.84310004-3.0992
Inactive100040.2088-0.50992.4533-1.9209-0.41840.4617-1.05255.94946.28828.7636-0.5450.9216-2.79590.208810004-1.4861
Inconclusive49.734642.262210Partial curve; partial efficacy-4.303310.807245.23142.96912.20 0 0 0 0 0 0 0 0 0 0 0 0 0 039.7015-0.61882.84480.88810.00942.76685.875211.958.22448.9497.06849.448122.15539.701510004-4.3489
Inconclusive30.869639.274510Partial curve; partial efficacy-4.51052.63840.979938.9369-0.33752.20 0 0 0 0 0 0 0 0 0 0 0 0 0 038.3807-0.22181.8163-0.7660.9433-1.62850.7273-1.86440.5114-1.39731.36159.830428.899138.380710004-3.1002
Inconclusive62.725631.99510Partial curve; partial efficacy; poor fit-4.20263.24750.808229-2.9952.40 0 0 0 0 0 0 0 0 0 0 0 0 0 023.8094-4.1625-1.3901-1.5226-0.3825-8.32920.3951-6.4986-0.4749-5.7267-0.3547-1.45245.496723.809410004-4.0375
Inactive10-4.39591.69240.5803-7.38343.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.8195-0.15651.02455.34581.68774.78684.9925.87394.32077.04250.0148-0.2167-0.2419-7.8195100040.8078
Inactive10-5.99513.92950.3374-3.0208240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.7098-0.61051.9344.08050.45173.65393.7594-0.97033.256-6.2855-0.62940.2278-0.9853-6.7098100040.5022
Inactive10-4.06410.80.6276240.821840 0 0 0 0 0 0 0 0 0 0 0 0 0 017.14390.83390.9785-2.37282.60513.2312-0.1354-1.67722.75114.08237.28953.67335.072317.143910004-1.6432
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53MS574
Protocol: Please refer to other AIDs 1963577 and 1963579 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the p53 with human microsomes agonist mode assay (AID 1963577), cell viability counter screen (AID 1963579), and auto fluorescence counter screens (AID 720687, 720685, 720678, and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
active agonistactive agonist1.217408778.37631949inconclusive agonistactive agonist0.64630334178.39811596inactive0inactiveLightBiologicals
active agonistactive agonist0.43195290759.28553099active agonist0.91292773444.30993466active agonist0.55433172482.63203296inactive0inactiveLightBiologicals
active agonistactive agonist1.92946276175.72635936inconclusive agonistactive agonist1.39241833793.4523553inactive0inactiveLightBiologicals
active agonistactive agonist0.90676599358.50333518active agonist0.30731181552.96240355active agonist0.50725702284.98953543inactive0inactiveLightBiologicals
active agonistactive agonist0.46322605451.84457808active agonist0.58316704959.08400159active agonist0.56121117687.34471148inactive0inconclusiveCrescent
active agonistactive agonist3.97431503881.35179825inconclusive antagonist6.298864848-55.06041593inconclusive agonistactive antagonist8.897383087-112.1712623inactiveMicrosource
active agonistactive agonist2.57297994471.82694939inconclusive agonistactive agonist1.5623190775.01686917inactive0inactiveLightBiologicals
active agonistactive agonist0.96702210456.88216128inconclusive agonistactive agonist0.813647772.2886186inactive0inactiveLightBiologicals
active agonistactive agonist2.16489282570.10936057inconclusive agonist0.16234405951.55911786active agonist0.78301437374.08029793inactive0inactiveSIGMA
active agonistactive agonist1.18648510457.37963601active agonist2.1099020365.82498706active agonist1.30595723699.20329811inactive0inactiveSequoia
active agonistactive agonist0.94245861853.83876935inactive0active agonist1.12011416783.34522444inactive0inactivePharmaron
active agonistactive agonist1.13670862258.22057975active agonist0.38813471546.97356994active agonist0.69021197284.87369086inactive0inactiveSigmaAldrich
active agonistactive agonist1.37140703260.17931711inconclusive agonist8.16895252360.48218607active agonist3.94003160970.47314257inactive0inactiveFisher
active agonistactive agonist1.30131434158.4681202inconclusive agonistactive agonist0.88657513973.04049532inactive0inconclusiveSIGMA
active agonistactive agonist0.43195290746.46415354active agonist1.02432176549.29568673active agonist0.57601845974.36852288inactive0Sigma Chemical Company
active agonistactive agonist2.1099020362.60069161inconclusive agonistactive agonist1.20947145569.12030947inactive0inactiveSIGMA
active agonistactive agonist3.97431503876.85083297inconclusive agonist0.0792980148.75406392active agonist1.844713627108.3175397inactive0inactiveChemos
active agonistactive agonist4.07789839875.41728704inconclusive agonistactive agonist5.54331724488.76279206inactive0inactiveLightBiologicals
active agonistactive agonist3.23918983670.70756618inconclusive agonistactive agonist4.40321340175.21515029inactive0inactiveLightBiologicals
active agonistactive agonist3.84978433576.47198713inconclusive agonistactive agonist2.29317078985.70280133inactive0inactiveSIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53654
Protocol: Please refer to other AIDs 1963582 and 1963581 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the p53 agonist mode assay (AID 1963582), cell viability counter screen (AID 1963581), and auto fluorescence counter screens (AID 720687, 720685, 720678, and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
active agonistactive agonist0.047234823152.29472inactive0active agonist0.037519953136.8633354inactive0GVK
active agonistactive agonist0.844238379220.2162354inconclusive antagonistactive agonist0.512623398104.6191287inactive0inactiveToronto Research
active agonistactive agonist0.012094715104.4361664inconclusive agonistactive agonist0.011201142144.4467864active antagonist0.397431504-70.21237763inactiveSelleck
active agonistactive agonist1.209471455180.1226065inactive0active agonist0.606171653113.571674inconclusive agonistinactiveSequoia
active agonistactive agonist2.778239835211.6412216inconclusive agonist48.4659132967.35167123active agonist5.13376992205.3954222inactive0inconclusiveSigmaAldrich
active agonistactive agonist13.57817889353.547094active antagonist13.06696898-36.85413308active agonist12.57500577253.5649028active agonist2.9828481548.90133363inactiveMicrosource
active agonistactive agonist0.13570492993.31141224inconclusive antagonist0.188045216-22.20736842active agonist0.14101401985.04743995inactive0inactiveSequoia
active agonistactive agonist0.16450339394.32096258inconclusive antagonistactive agonist0.36827722384.98769167inconclusive agonistinactivePrestwick
active agonistactive agonist9.486435714254.9932329active antagonist5.985536287-48.49725447active agonist8.136476998139.346131inactive0inactivePharma
active agonistactive agonist8.399671273237.8402483active antagonist1.410140188-48.09733887active agonist7.071445409180.865123inconclusiveinactiveMicrosource
active agonistactive agonist0.09129277384.95609526inactive0active agonist0.05437964977.70981018inactive0inconclusiveAcros
active agonistactive agonist4.38376925182.3000923active antagonist5.111099704-51.21597367active agonist3.48215169122.7336497inactive0inactiveSigmaAldrich
active agonistactive agonist1.993004104142.3810228inconclusive antagonistactive agonist5.202054047130.3026231inactive0inconclusiveSIGMA
active agonistactive agonist0.500619997103.8418341inactive0active agonist0.856725169155.0303204inconclusive antagonist0.562341325-43.25974821inactiveVitas
active agonistactive agonist0.12094714681.97009147inconclusive agonistactive agonist0.103735871123.2085258active antagonist0.70674426-72.37265734inactiveSequoia
active agonistactive agonist2.815193123137.0716961active antagonist3.159593015-33.41462647active agonist2.15199632892.29790016inactive0inactiveMicrosource
active agonistactive agonist0.61789561391.22925261inactive0active agonist1.809596631101.0029829inactive0inconclusiveSIGMA
active agonistactive agonist0.55433172483.79635801inactive0active agonist1.39241833788.81361331inactive0inactiveSIGMA
active agonistactive agonist0.43195290778.01689897inconclusive agonistactive agonist0.37766180899.59298459active agonist0.51337699277.40150829inactiveRoche
active agonistactive agonist2.605727258108.4007283inconclusive agonistactive agonist1.916883076121.5082983active antagonist2.507623262-38.90785093inactiveMicrosource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: HTR2A603
Protocol: Assay Protocol Summary:

HTR2A-CHO cells were dispensed at 2000 cells/3uL/well in 1536-well black-clear bottom plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 h, 3 uL of Dye Loading Buffer was transferred to the assay plate by a Flying Reagent Dispenser. The assay plates were incubated at 37 C for 1h. For agonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 2 min at 1 sec intervals.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049636 uM-Replicate_1Activity at 0.0000112894 uM-Replicate_1Activity at 0.0000451294 uM-Replicate_1Activity at 0.0001083383 uM-Replicate_1Activity at 0.0002490219 uM-Replicate_1Activity at 0.0005090755 uM-Replicate_1Activity at 0.00139 uM-Replicate_1Activity at 0.00429 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.128 uM-Replicate_1Activity at 0.292 uM-Replicate_1Activity at 0.874 uM-Replicate_1Activity at 2.651 uM-Replicate_1Activity at 7.023 uM-Replicate_1Activity at 15.88 uM-Replicate_1Activity at 35.56 uM-Replicate_1Activity at 76.84 uM-Replicate_1Activity at 198.7 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-5.67131.10.547980.819540 0 0 0 0 0 0 0 0 0 0 0 0 0 08.7235-1.7246-0.79674.02471.9622-1.14673.4822-1.5146-1.8176.06554.31945.62146.74618.7235QC'd by ACCInactive0
Inactive00040.71362.84913.15472.62081.73272.79433.62882.21110.9461-1.0072-0.4977-1.0290.49570.7136QC'd by ACCInactive0-6.67134.95490.4722
Activator23.9145533.488243Partial curve; high efficacy-4.62131.98870.987537.0293.54082.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0406.84010.49816.65853.85970.56377.39464.5987-3.71610.781112.19813.264681.5331158.4589406.8401QC'd by ACCActivator18.9959357.953744Partial curve; high efficacy-4.72131.34430.9586
Inactive0004-3.33330.3686-2.1838-0.97840.28920.0634-2.0419-0.18710.061-3.3304-2.6853-2.00990.2108-3.3333QC'd by ACCInactive0
Inactive00043.36520.94171.36941.3511-0.11411.40170.29941.14555.12170.75433.87762.18824.52673.3652QC'd by RTIInactive0
Inactive0-4.96951.88510.9211-14.6405140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.45042.42870.3370.34840.7070.60323.1373-1.09171.7571-3.2954-1.1568-10.861-12.9725-13.4504QC'd by RTIInactive0-4.41952.18760.6553
Activator0.075282.249290Complete curve; high efficacy-7.12350.80.98879.7492-2.51.10 0 0 0 0 0 0 0 0 0 0 0 0 0 080.83461.78786.13089.925819.761739.591652.77160.918266.105569.033480.327881.334383.594680.8346QC'd by RTIActivator0.474788.523888Complete curve; high efficacy-6.32350.90.9909
Activator0.265393.198289Complete curve; high efficacy-6.57630.80.995589.1185-4.07971.10 0 0 0 0 0 0 0 0 0 0 0 0 0 090.5676-0.8998-0.035-0.36238.222717.297432.011448.365862.041171.971786.9385.895983.583490.5676QC'd by RTIActivator0.026577.546693Complete curve; high efficacy-7.57630.90.987
Inactive0-4.13091.24750.8779-16.497-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.58080.1628-0.5762-1.1136-0.2048-0.368-0.8819-0.8283-2.0195-1.2058-1.9466-7.6162-7.0211-14.5808QC'd by RTIInactive0
Inactive0004-6.6585-1.8147-3.036-2.7414-2.9382-3.1098-0.24922.1427-2.6629-0.1939-2.7488-1.4566-8.5268-6.6585QC'd by RTIInactive0
Inactive0004-3.4757-0.43290.3326-0.84020.0544-2.7307-0.3172-1.3413-2.0597-1.0047-1.1604-1.2522-8.0139-3.4757QC'd by RTIInactive0-4.0751.10.6917
Activator57.586431.97110Partial curve; partial efficacy; poor fit-4.23974.95490.909830-1.9712.40 0 0 0 0 0 0 0 0 0 0 0 0 0 024.7904-1.4056-0.3633-0.0089-3.0195-0.599-0.5758-0.7948-0.4323-4.1986-5.0136-5.39250.354724.7904QC'd by RTIInactive0
Activator62.154948.383510Single point of activity-4.20654.95490.969648.1294-0.254130 0 0 0 0 0 0 0 0 0 0 0 0 0 039.8328-0.49521.4760.66241.9344-0.3395-0.7123-1.4037-1.73662.2992-2.7117-1.43311.585639.8328QC'd by RTIActivator55.395689.54741Partial curve; high efficacy-4.25652.58840.9752
Inactive0004-1.5545-1.6566-2.6838-1.6155-1.2771-2.8033-0.7992-2.2086-2.1165-1.43662.10792.0395-0.1964-1.5545QC'd by RTIInactive0
Inactive0-6.44991.96730.9648-15.489-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.8883-0.1006-0.005-1.1316-1.8411-1.5843-1.4803-6.9758-12.1972-15.4653-17.0742-15.8774-16.437-11.8883QC'd by RTIInactive0-7.24990.90.9292
Inactive0-6.7574.95490.7181-12.0035140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.7465-0.46011.86560.11251.6950.44190.0198-17.5030.0822-10.7704-15.9134-13.7319-15.7608-11.7465QC'd by RTIInactive0-6.6074.95490.7096
Inactive0-5.39891.62660.717541440 0 0 0 0 0 0 0 0 0 0 0 0 0 02.18889.749913.244215.360917.054711.082914.114214.655317.559610.40557.12343.60218.61112.1888QC'd by RTIInactive0
Activator0.00149.315210Complete curve; high efficacy; poor fit-8.99190.40.646890.475241.161.30 0 0 0 0 0 0 0 0 0 0 0 0 0 087.673963.476275.320673.937776.90881.009883.341778.7232103.994589.298187.72991.364785.620587.6739QC'd by RTIActivator5.0E-480.912699Complete curve; high efficacy-9.29190.60.7869
Activator1.440861.767884Complete curve; high efficacy-5.84141.47870.990864.30992.54211.10 0 0 0 0 0 0 0 0 0 0 0 0 0 062.09883.60835.35485.57370.9311-2.04832.24227.913418.225242.68557.609265.591966.455462.0988QC'd by RTIActivator1.616683.116985Complete curve; high efficacy-5.79140.80.9937
Inactive0-5.36041.96730.3672-14.2663-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.6859-5.5953-3.7533-2.9145-1.4897-2.1001-2.8826.1673-6.0115-4.3461-9.4884-15.1664-14.9205-12.6859QC'd by RTIInactive0-5.56044.0950.9954
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: HTR2A875
Protocol: Tox21 Assay Protocol Summary:

HTR2A-CHO cells were dispensed at 2000 cells/3uL/well in 1536-well black-clear bottom plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 h, 3 uL of Dye Loading Buffer was transferred to the assay plate by a Flying Reagent Dispenser. The assay plates were incubated at 37 C for 1h. For antagonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. After 5 min incubation at room temperature, 1.5 uL of 4-Iodo-2,5-dimethoxy-alpha-methylbenzeneethanamine hydrochloride (DOI) at 4nM was added to each well. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 3 min at 1 sec intervals.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000039737 uM-Replicate_1Activity at 0.0000090357 uM-Replicate_1Activity at 0.0000361304 uM-Replicate_1Activity at 0.0000867348 uM-Replicate_1Activity at 0.0001993648 uM-Replicate_1Activity at 0.0004075545 uM-Replicate_1Activity at 0.00112 uM-Replicate_1Activity at 0.00343 uM-Replicate_1Activity at 0.00899 uM-Replicate_1Activity at 0.020 uM-Replicate_1Activity at 0.046 uM-Replicate_1Activity at 0.103 uM-Replicate_1Activity at 0.233 uM-Replicate_1Activity at 0.700 uM-Replicate_1Activity at 2.122 uM-Replicate_1Activity at 5.622 uM-Replicate_1Activity at 12.72 uM-Replicate_1Activity at 28.47 uM-Replicate_1Activity at 61.52 uM-Replicate_1Activity at 159.1 uM-Replicate_1Activity at 580.7 uM-Replicate_1Activity at 1231.0 uM-Replicate_1Activity at 2752.0 uM-Replicate_1Activity at 6155.0 uM-Replicate_1Activity at 13760.0 uM-Replicate_1Activity at 30770.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-7.2061-3.526-9.9489-2.97267.0388-5.0617-5.7675-3.6219-0.0251-2.7206-1.11990.8657-10.4359-7.2061QC'd by SIGMAInactive0
Inactive00046.13445.64138.53264.04038.44095.441410.92884.31674.82284.80260.47619.71629.14296.1344QC'd by WaterstoneInactive0-8.6263.06540.5917
Inactive00042.3205-1.4158-3.9188-1.2064-7.0528-5.2123-2.2684-6.0073-2.0124-4.3471-2.4408-5.7061-1.99452.3205QC'd by SIGMAInactive0
Inactive00040.29564.40161.67061.4091-1.97283.5850.63440.38270.4984-2.7333.67393.46242.37810.2956QC'd by LightBiologicalsInactive0
Inactive0004-6.96170.1347-10.9722-11.3789-0.9886-3.2185-2.6238-5.3048-2.66760.8444-8.24951.4346-0.1703-6.9617QC'd by LightBiologicalsInactive0
Inactive0-4.9264.95490.47717-3.149540 0 0 0 0 0 0 0 0 0 0 0 0 0 08.9844-4.3701-1.7004-8.87464.1299-5.48120.94572.1614-3.6786-2.2479-8.06382.37734.41318.9844QC'd by SIGMAInactive0
Inactive00042.7598-1.388-10.7501-2.243-7.1709-7.7234-0.86450.53450.11642.5902-8.76125.54313.50742.7598QC'd by LightBiologicalsInactive0
Inactive0-5.65821.46410.408-4.6092240 0 0 0 0 0 0 0 0 0 0 0 0 0 10.78232.28384.9364.2099-4.16470.83986.4512-0.0288-0.01385.2677-3.4901-4.5008-2.3051-5.0910.7823QC'd by SIGMAInactive0
Inactive00043.79320.7208-1.6962-3.28710.9942-4.8215.321-4.7996-0.71224.43679.43390.65277.89283.7932QC'd by SIGMAInactive0
Inactive00041.00171.7707-1.3919-0.9574.20364.12342.9095-0.1743.60228.54267.03274.49020.66171.0017QC'd by TCIInhibitor0.167523.871710Single point of activity-6.7764.95490.6462
Inactive00041.3141-0.92173.5166-2.30331.6783.27250.5745-9.0E-41.5868-0.40153.79654.99052.65621.3141QC'd by SIGMAInactive0
Inactive0-5.62610.41615-3.772340 0 0 0 0 0 0 0 0 0 0 0 0 0 06.036-2.1149-5.697-13.97690.09992.219-1.9463-2.9706-3.34883.16550.39146.03741.34256.036QC'd by SIGMAInactive0
Inhibitor9.419843.686410Single point of activity-5.0264.95490.8559-47.6864-4-30 0 0 0 0 0 0 0 0 0 0 0 0 1 1-4.2356-9.8138-9.423-4.05922.411-1.0589-7.4879-2.3574-4.7276-3.6806-4.4603-38.39886.5491-4.2356QC'd by LightBiologicalsInactive0-7.0260.20.4384
Inactive0004-0.06471.12492.86741.33545.11772.14-1.44271.18032.9089-1.5124-0.02495.72685.9847-0.0647QC'd by LightBiologicalsInhibitor47.210925.535310Partial curve; partial efficacy; poor fit-4.3264.95490.7127
Inactive0-6.42610.55530.5-8.527640 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.5555-7.8118-8.811-10.011-6.4119-10.1734-6.8978-2.0059-5.3563.4401-1.34733.18-0.9271-0.5555QC'd by LightBiologicalsInactive0
Inactive00041.97624.76444.171228.06640.678-1.83649.05051.55284.31155.40685.86384.23756.04841.9762QC'd by SIGMAInactive0
Inactive0004-2.38713.6232-0.273903.5491.08915.48920.99120.71813.3244-2.86665.65283.6147-2.3871QC'd by LightBiologicalsInactive0
Inactive000413.15252.6229-1.041215.1602-2.820813.804212.821710.52165.190911.06815.40983.05368.005213.1525QC'd by SIGMAInactive0
Inactive0-5.2761.10.6487-16.0176-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.848-6.15315.9102-2.0982-1.5437-3.338-2.63271.5609-0.7495-10.8518-7.7926-9.3193-14.5467-15.848QC'd by LightBiologicalsInactive0-4.6261.3310.6582
Inactive00040.0466-2.72680.2154-0.12984.7191-1.4011-1.10474.8769-0.64661.98962.8818-2.35198.50421.5602QC'd by AcrosInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EMI141217_green
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 80% are deemed active, and the activity outcome is set to 2.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample numberSample NameSupplierAC50 (uM)Curve Class2EfficacyChannel
4trans-Aconitic acidSpecs0.6314-10.976Green
10NEROLMicrosource12.58934-28.228Green
3Phenol redLabotest0.7079419.263Green
4Aminoquinuride dihydrochlorideLabotest0.7079418Green
3Pyridoxamine DihydrochlorideBosche15.84894-11.767Green
7CarzenideLabotest0.631411.002Green
9PridinolSpecs102.236.664Green
3L-LeucineBosche0.8913414.333Green
6FenticlorVitas3.16234-28.657Green
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource39.8107-3-98.319Green
8BenzbromaroneLabotest1.7783416.5Green
8Phosphonoacetic acidSIGMA14-15.333Green
17DomperidoneMicrosource25.11892.3125.472Green
4PifexoleBionet0.6314-9.778Green
15WY-14643SIGMA3.9811419.845Green
14OXAPROZINMicrosource39.8107418.153Green
6Topotecan hydrochloridePrestwick31.622851429.488Green
12AZELAIC ACIDMicrosource10417.221Green
13AmoxapineEnzo8.91252.394.86Green
14R-(+)-AtenololVitas104-16.344Green
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen1_EMI141217blue
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 80% are deemed active, and the activity outcome is set to 2.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample numberSample NameSupplierAC50 (uM)Curve Class2EfficacyChannel
1Benztropine methylsulfonateNCI5.01191.1125.342blue
13,5,3'-TriiodothyronineNCI0.56234-19.671blue
9Cyclobenzaprine hydrochlorideMicrosource12.58931.189.572blue
1Nortriptyline hdrochlorideNCI8.91251.1103.212blue
7Topotecan hydrochlorideSIGMA0.39814-20.604blue
13AmoxapineEnzo14.12542.1119.337blue
14R-(+)-AtenololVitas2.8184-2.4-17.451blue
11Amantadine hydrochlorideVitas35.4813418.78blue
14AzathioprineSIGMA7.9433421.715blue
13AciclovirMicrosource11.2202414.099blue
14AcetazolamideSpecs0.70794-6.228blue
4AcetylcysteineMicrosource0.70794-10.721blue
10Aminocaproic acidMicrosource11.2202423.484blue
15AMITRIPTYLINE HYDROCHLORIDEMicrosource11.22021.1101.386blue
17Amiodarone hydrochlorideMicrosource6.30961.1105.656blue
15AltretamineMicrosource2.238745.918blue
17Phenoxybenzamine hydrochlorideMicrosource17.7828417.722blue
11Bupropion hydrochlorideMicrosource0.89134-12.736blue
11BROMPHENIRAMINE MALEATEMicrosource28.18382.279.524blue
15BaclofenVitas0.0032419.679blue